1
|
Sinyor M, Ekstein D, Prabaharan N, Fiksenbaum L, Vandermeer C, Schaffer A, Pirkis J, Heisel MJ, Goldstein BI, Redelmeier DA, Taylor P, Niederkrotenthaler T. Changes in Media Reporting Quality and Suicides Following National Media Engagement on Responsible Reporting of Suicide in Canada: Changements de la Qualité des reportages dans les médias sur les suicides suite à l'engagement des médias nationaux à la déclaration responsable du suicide au Canada. Can J Psychiatry 2024; 69:358-368. [PMID: 38174363 PMCID: PMC11032096 DOI: 10.1177/07067437231223334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2024]
Abstract
OBJECTIVE Responsible media reporting is an accepted strategy for preventing suicide. In 2015, suicide prevention experts launched a media engagement initiative aimed at improving suicide-related reporting in Canada; its impact on media reporting quality and suicide deaths is unknown. METHOD This pre-post observational study examined changes in reporting characteristics in a random sample of suicide-related articles from major publications in the Greater Toronto Area (GTA) media market. Articles (n = 900) included 450 from the 6-year periods prior to and after the initiative began. We also examined changes in suicide counts in the GTA between these epochs. We used chi-square tests to analyse changes in reporting characteristics and time-series analyses to identify changes in suicide counts. Secondary outcomes focused on guidelines developed by media professionals in Canada and how they may have influenced media reporting quality as well as on the overarching narrative of media articles during the most recent years of available data. RESULTS Across-the-board improvement was observed in suicide-related reporting with substantial reductions in many elements of putatively harmful content and substantial increases in all aspects of putatively protective content. However, overarching article narratives remained potentially harmful with 55.2% of articles telling the story of someone's death and 20.8% presenting an other negative message. Only 3.6% of articles told a story of survival. After controlling for potential confounders, a nonsignificant numeric decrease in suicide counts was identified after initiative implementation (ω = -5.41, SE = 3.43, t = 1.58, p = 0.12). CONCLUSIONS We found evidence that a strategy to engage media in Canada changed the content of reporting, but there was only a nonsignificant trend towards fewer suicides. A more fundamental change in media narratives to focus on survival rather than death appears warranted.
Collapse
Affiliation(s)
- Mark Sinyor
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada
- Department of Psychiatry, University of Toronto, Toronto, Canada
| | - Daniella Ekstein
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Nivetha Prabaharan
- Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, Canada
| | | | - Caroline Vandermeer
- Viterbi School of Engineering, University of Southern California, Los Angeles, USA
| | - Ayal Schaffer
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada
- Department of Psychiatry, University of Toronto, Toronto, Canada
| | - Jane Pirkis
- Centre for Mental Health, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia
| | - Marnin J. Heisel
- Department of Psychiatry, The University of Western Ontario, London, Canada
| | - Benjamin I. Goldstein
- Department of Psychiatry, University of Toronto, Toronto, Canada
- Centre for Youth Bipolar Disorder, Center for Addiction and Mental Health, Toronto, Canada
| | - Donald A. Redelmeier
- Institute for Clinical Evaluative Sciences, Toronto, Canada
- Department of Medicine, University of Toronto, Toronto, Canada
- Division of General Internal Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Paul Taylor
- Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Thomas Niederkrotenthaler
- Unit Suicide Research and Mental Health Promotion, Department of Social and Preventive Medicine, Centre for Public Health, Medical University of Vienna, Vienna, Austria
- Wiener Werkstaette for Suicide Research, Vienna, Austria
| |
Collapse
|
2
|
Schaffer A, Malhi GS. A new model for the prevention of suicide in bipolar disorder: Every patient, every setting, every provider. Bipolar Disord 2024. [PMID: 38644491 DOI: 10.1111/bdi.13442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/23/2024]
Affiliation(s)
- Ayal Schaffer
- Department of Psychiatry, University of Toronto, Toronto, Canada
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Gin S Malhi
- Academic Department of Psychiatry, Kolling Institute, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
- CADE Clinic and Mood-T, Royal North Shore Hospital, Northern Sydney Local Health District, Sydney, New South Wales, Australia
- Department of Psychiatry, University of Oxford, Oxford, UK
- Oxford Uehiro Centre for Practical Ethics, Faculty of Philosophy, University of Oxford, Oxford, UK
| |
Collapse
|
3
|
Hatcher S, Sinyor M, Edgar NE, Schaffer A, MacLean SE, Carleton RN, Colman I, Jayakumar N, Ward B, Zaheer R. A Comparison of Suicides in Public Safety Personnel With Suicides in the General Population in Ontario, 2014 to 2018. Crisis 2024. [PMID: 38597229 DOI: 10.1027/0227-5910/a000953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/11/2024]
Abstract
Background: There is conflicting evidence on the suicide rates of different public safety personnel (PSP). There have been few studies that compare suicides in PSP with the general population and none that have used a detailed comparison of coroner records. Aims: The current study estimates suicide rates among different PSP and compares PSP suicides with the general population. Method: We identified coroner records of PSP suicides from January 2014 to December 2018 and compared each one to two matched general population controls. Results: We identified 36 PSP suicides and 72 general population controls. Police had a higher suicide rate than other PSP groups. PSP were more likely to die by firearm, be separated/divorced or married, die in a motor vehicle, have problems at work, and have a PTSD diagnosis. PSP were less likely to die by jumping. Limitations: The study may have not identified all PSP suicides. Apart from the cause of death, data in coroner records are not systematically collected, so information may be incomplete. Conclusion: PSP suicides appear different than the general population. Death records need to have an occupation identifier to enable monitoring of trends in occupational groups, such as PSP.
Collapse
Affiliation(s)
- Simon Hatcher
- Department of Psychiatry, University of Ottawa, ON, Canada
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, ON, Canada
| | - Mark Sinyor
- Department of Psychiatry, University of Toronto, ON, Canada
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - Nicole E Edgar
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, ON, Canada
| | - Ayal Schaffer
- Department of Psychiatry, University of Toronto, ON, Canada
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - Sarah E MacLean
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, ON, Canada
- School of Journalism and Communication, Carleton University, Ottawa, ON, Canada
| | - R Nicholas Carleton
- Anxiety and Illness Behaviours Laboratory, Department of Psychology, University of Regina, SK, Canada
- Canadian Institute for Public Safety Research and Treatment, University of Regina, SK, Canada
| | - Ian Colman
- School of Epidemiology and Public Health, University of Ottawa, ON, Canada
| | - Navitha Jayakumar
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - Brooklyn Ward
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, ON, Canada
- Health and Rehabilitation Sciences, Western University, London, ON, Canada
| | - Rabia Zaheer
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| |
Collapse
|
4
|
Gordon M, Jayakumar N, Atzema C, Korczak DJ, Kennedy S, Schaffer A, Goldstein B, Orser BA, Yee D, Fiksenbaum L, Choi LHL, Phillips A, McFarlan A, Kreller M, Freedman C, Tanenbaum B, McDowall D, Ceniti A, Sinyor M. Self-harm presentations to hospital trauma centre emergency departments during the first year of the COVID-19 pandemic. Psychiatry Res 2024; 336:115892. [PMID: 38642422 DOI: 10.1016/j.psychres.2024.115892] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/14/2023] [Revised: 04/01/2024] [Accepted: 04/02/2024] [Indexed: 04/22/2024]
Abstract
The COVID-19 pandemic raised concerns regarding increased suicide-related behaviours. We compared characteristics and counts of Emergency Department (ED) presentations for self-harm, an important suicide-related outcome, during versus prior to the pandemic's first year. We included patients presenting with self-harm to the ED of two trauma centres in Toronto, Canada. Time series models compared intra-pandemic (March 2020-February 2021) presentation counts to predictions from pre-pandemic data. The self-harm proportion of ED presentations was compared between the intra-pandemic period and preceding three years. A retrospective chart review of eligible patients seen from March 2019-February 2021 compared pre- vs. intra-pandemic patient and injury characteristics. While monthly intra-pandemic self-harm counts were largely within expected ranges, the self-harm proportion of total presentations increased. Being widowed (OR=9.46; 95 %CI=1.10-81.08), employment/financial stressors (OR=1.65, 95 %CI=1.06-2.58), job loss (OR=3.83; 95 %CI=1.36-10.76), and chest-stabbing self-harm (OR=2.50; 95 %CI=1.16-5.39) were associated with intra-pandemic presentations. Intra-pandemic self-harm was also associated with Intensive Care Unit (ICU) admission (OR=2.18, 95 %CI=1.41-3.38). In summary, while the number of self-harm presentations to these trauma centres did not increase during the early pandemic, their proportion was increased. The association of intra-pandemic self-harm with variables indicating medically severe injury, economic stressors, and being widowed may inform future suicide and self-harm prevention strategies.
Collapse
Affiliation(s)
- Madeleine Gordon
- Sunnybrook Health Sciences Centre. 2075 Bayview Ave, Toronto M4N 3M5, ON, Canada; Temerty Faculty of Medicine, University of Toronto. 1 King's College Circle, Toronto M5S 1A8, ON, Canada; Faculty of Medicine, University of Ottawa. 451 Smyth Rd, Ottawa K1H 8M5, ON, Canada.
| | - Navitha Jayakumar
- Sunnybrook Health Sciences Centre. 2075 Bayview Ave, Toronto M4N 3M5, ON, Canada
| | - Clare Atzema
- Sunnybrook Health Sciences Centre. 2075 Bayview Ave, Toronto M4N 3M5, ON, Canada; Temerty Faculty of Medicine, University of Toronto. 1 King's College Circle, Toronto M5S 1A8, ON, Canada
| | - Daphne J Korczak
- Temerty Faculty of Medicine, University of Toronto. 1 King's College Circle, Toronto M5S 1A8, ON, Canada; The Hospital for Sick Children, 555 University Ave, Toronto M5G 1X8, ON, Canada
| | - Sidney Kennedy
- Temerty Faculty of Medicine, University of Toronto. 1 King's College Circle, Toronto M5S 1A8, ON, Canada; St. Michael's Hospital. 36 Queen St E, Toronto M5B 1W8, ON, Canada
| | - Ayal Schaffer
- Sunnybrook Health Sciences Centre. 2075 Bayview Ave, Toronto M4N 3M5, ON, Canada; Temerty Faculty of Medicine, University of Toronto. 1 King's College Circle, Toronto M5S 1A8, ON, Canada
| | - Benjamin Goldstein
- Temerty Faculty of Medicine, University of Toronto. 1 King's College Circle, Toronto M5S 1A8, ON, Canada; Centre for Addiction and Mental Health. 250 College St, Toronto M5T 1R8, ON, Canada
| | - Beverley A Orser
- Sunnybrook Health Sciences Centre. 2075 Bayview Ave, Toronto M4N 3M5, ON, Canada; Temerty Faculty of Medicine, University of Toronto. 1 King's College Circle, Toronto M5S 1A8, ON, Canada
| | - Doreen Yee
- Sunnybrook Health Sciences Centre. 2075 Bayview Ave, Toronto M4N 3M5, ON, Canada; Temerty Faculty of Medicine, University of Toronto. 1 King's College Circle, Toronto M5S 1A8, ON, Canada
| | - Lisa Fiksenbaum
- Sunnybrook Health Sciences Centre. 2075 Bayview Ave, Toronto M4N 3M5, ON, Canada; Temerty Faculty of Medicine, University of Toronto. 1 King's College Circle, Toronto M5S 1A8, ON, Canada; York University. 4700 Keele St, Toronto M3J 1P3, ON, Canada
| | - Liz Hanbyul Lee Choi
- Sunnybrook Health Sciences Centre. 2075 Bayview Ave, Toronto M4N 3M5, ON, Canada
| | - Andrea Phillips
- Sunnybrook Health Sciences Centre. 2075 Bayview Ave, Toronto M4N 3M5, ON, Canada
| | - Amanda McFarlan
- St. Michael's Hospital. 36 Queen St E, Toronto M5B 1W8, ON, Canada
| | - Margaret Kreller
- The Hospital for Sick Children, 555 University Ave, Toronto M5G 1X8, ON, Canada
| | - Corey Freedman
- Sunnybrook Health Sciences Centre. 2075 Bayview Ave, Toronto M4N 3M5, ON, Canada
| | - Brandy Tanenbaum
- Sunnybrook Health Sciences Centre. 2075 Bayview Ave, Toronto M4N 3M5, ON, Canada
| | - Dorothy McDowall
- The Hospital for Sick Children, 555 University Ave, Toronto M5G 1X8, ON, Canada
| | - Amanda Ceniti
- St. Michael's Hospital. 36 Queen St E, Toronto M5B 1W8, ON, Canada
| | - Mark Sinyor
- Sunnybrook Health Sciences Centre. 2075 Bayview Ave, Toronto M4N 3M5, ON, Canada; Temerty Faculty of Medicine, University of Toronto. 1 King's College Circle, Toronto M5S 1A8, ON, Canada
| |
Collapse
|
5
|
Miskowiak KW, Obel ZK, Gugliemo R, Bonnin CDM, Bowie CR, Balanzá-Martínez V, Burdick KE, Carvalho AF, Dols A, Douglas K, Gallagher P, Kessing LV, Lafer B, Lewandowski KE, López-Jaramillo C, Martinez-Aran A, McIntyre RS, Porter RJ, Purdon SE, Schaffer A, Stokes PRA, Sumiyoshi T, Torres IJ, Van Rheenen TE, Yatham LN, Young AH, Vieta E, Hasler G. Efficacy and safety of established and off-label ADHD drug therapies for cognitive impairment or attention-deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force. Bipolar Disord 2024. [PMID: 38433530 DOI: 10.1111/bdi.13414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/05/2024]
Abstract
BACKGROUND Abnormalities in dopamine and norepinephrine signaling are implicated in cognitive impairments in bipolar disorder (BD) and attention-deficit hyperactivity disorder (ADHD). This systematic review by the ISBD Targeting Cognition Task Force therefore aimed to investigate the possible benefits on cognition and/or ADHD symptoms and safety of established and off-label ADHD therapies in BD. METHODS We included studies of ADHD medications in BD patients, which involved cognitive and/or safety measures. We followed the procedures of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 statement. Searches were conducted on PubMed, Embase and PsycINFO from inception until June 2023. Two authors reviewed the studies independently using the Revised Cochrane Collaboration's Risk of Bias tool for Randomized trials. RESULTS Seventeen studies were identified (N = 2136), investigating armodafinil (k = 4, N = 1581), methylphenidate (k = 4, N = 84), bupropion (k = 4, n = 249), clonidine (k = 1, n = 70), lisdexamphetamine (k = 1, n = 25), mixed amphetamine salts (k = 1, n = 30), or modafinil (k = 2, n = 97). Three studies investigated cognition, four ADHD symptoms, and 10 the safety. Three studies found treatment-related ADHD symptom reduction: two involved methylphenidate and one amphetamine salts. One study found a trend towards pro-cognitive effects of modafinil on some cognitive domains. No increased risk of (hypo)mania was observed. Five studies had low risk of bias, eleven a moderate risk, and one a serious risk of bias. CONCLUSIONS Methylphenidate or mixed amphetamine salts may improve ADHD symptoms in BD. However, there is limited evidence regarding the effectiveness on cognition. The medications produced no increased mania risk when used alongside mood stabilizers. Further robust studies are needed to assess cognition in BD patients receiving psychostimulant treatment alongside mood stabilizers.
Collapse
Affiliation(s)
- Kamilla W Miskowiak
- Neurocognition and Emotion in Affective Disorders (NEAD) Centre, Department of Psychology, University of Copenhagen | Mental Health Services, Capital Region of Denmark, Copenhagen, Denmark
- Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark
| | - Zacharias K Obel
- Neurocognition and Emotion in Affective Disorders (NEAD) Centre, Department of Psychology, University of Copenhagen | Mental Health Services, Capital Region of Denmark, Copenhagen, Denmark
- Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark
| | - Riccardo Gugliemo
- Psychiatry Research Unit, University of Fribourg, Fribourg, Switzerland
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Genoa, Italy
| | - Caterina Del Mar Bonnin
- Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain
| | | | | | - Katherine E Burdick
- Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
- Department of Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Andre F Carvalho
- IMPACT Strategic Research Centre (Innovation in Mental and Physical Health and Clinical Treatment), Deakin University, Geelong, Victoria, Australia
| | - Annemieke Dols
- Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Katie Douglas
- Department of Psychological Medicine, University of Otago, Christchurch, New Zealand
| | - Peter Gallagher
- Faculty of Medical Sciences, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK
| | - Lars V Kessing
- Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Beny Lafer
- Bipolar Disorder Research Program, Institute of Psychiatry, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
| | - Kathryn E Lewandowski
- Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
- McLean Hospital, Schizophrenia and Bipolar Disorder Program, Belmont, Massachusetts, USA
| | - Carlos López-Jaramillo
- Research Group in Psychiatry, Department of Psychiatry, Universidad de Antioquia, Medellín, Colombia
| | - Anabel Martinez-Aran
- Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain
| | - Roger S McIntyre
- Mood Disorders Psychopharmacology Unit, Brain and Cognition Discovery Foundation, University of Toronto, Toronto, Canada
| | - Richard J Porter
- Department of Psychological Medicine, University of Otago, Christchurch, New Zealand
| | - Scot E Purdon
- Department of Psychiatry, University of Alberta, Edmonton, Canada
| | - Ayal Schaffer
- Department of Psychiatry, University of Toronto, Toronto, Canada
| | - Paul R A Stokes
- Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Tomiki Sumiyoshi
- Department of Preventive Intervention for Psychiatric Disorders, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan
| | - Ivan J Torres
- Department of Psychiatry, University of British Columbia, Vancouver, Canada
| | - Tamsyn E Van Rheenen
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne, Carlton, Australia
- Centre for Mental Health, Faculty of Health, Arts and Design, Swinburne University, Melbourne, Australia
| | - Lakshmi N Yatham
- Department of Psychiatry, University of British Columbia, Vancouver, Canada
| | - Allan H Young
- Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Eduard Vieta
- Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain
| | - Gregor Hasler
- Psychiatry Research Unit, University of Fribourg, Fribourg, Switzerland
| |
Collapse
|
6
|
Izadi N, Mitchell RHB, Giacobbe P, Nestor S, Steinberg R, Amini J, Sinyor M, Schaffer A. Suicide Assessment and Prevention in Bipolar Disorder: How Current Evidence Can Inform Clinical Practice. Focus (Am Psychiatr Publ) 2023; 21:380-388. [PMID: 38695007 PMCID: PMC11058945 DOI: 10.1176/appi.focus.20230011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/04/2024]
Abstract
Bipolar disorder is associated with a considerable risk of suicide, and this fact must be incorporated into management of all patients with the condition. This article highlights the importance of a more nuanced understanding of the factors associated with the increased risk of suicidal behavior in people diagnosed as having bipolar disorder and interventions that could mitigate it. Several sociodemographic, clinical, environmental, and other variables have been associated with suicide attempts or deaths in bipolar disorder. Youths with bipolar disorder are a particularly vulnerable group, and their trajectory of illness could be modified by early interventions. Several medications have been studied regarding their relationship to suicide risk in bipolar disorder, and interventional psychiatry is a newer area of research focus. Finally, community-based approaches can be incorporated into a comprehensive approach to suicide prevention. This article summarizes the current understanding of key variables that can help inform a clinical risk assessment of individuals and interventions that can be employed in suicide prevention in bipolar disorder.
Collapse
Affiliation(s)
- Niloofar Izadi
- Department of Psychiatry, Sunnybrook Health Sciences Centre, and Sunnybrook Research Institute, Toronto (all authors); Department of Psychiatry, University of Toronto, Toronto (Izadi, Mitchell, Giacobbe, Nestor, Steinberg, Sinyor, Schaffer)
| | - Rachel H B Mitchell
- Department of Psychiatry, Sunnybrook Health Sciences Centre, and Sunnybrook Research Institute, Toronto (all authors); Department of Psychiatry, University of Toronto, Toronto (Izadi, Mitchell, Giacobbe, Nestor, Steinberg, Sinyor, Schaffer)
| | - Peter Giacobbe
- Department of Psychiatry, Sunnybrook Health Sciences Centre, and Sunnybrook Research Institute, Toronto (all authors); Department of Psychiatry, University of Toronto, Toronto (Izadi, Mitchell, Giacobbe, Nestor, Steinberg, Sinyor, Schaffer)
| | - Sean Nestor
- Department of Psychiatry, Sunnybrook Health Sciences Centre, and Sunnybrook Research Institute, Toronto (all authors); Department of Psychiatry, University of Toronto, Toronto (Izadi, Mitchell, Giacobbe, Nestor, Steinberg, Sinyor, Schaffer)
| | - Rosalie Steinberg
- Department of Psychiatry, Sunnybrook Health Sciences Centre, and Sunnybrook Research Institute, Toronto (all authors); Department of Psychiatry, University of Toronto, Toronto (Izadi, Mitchell, Giacobbe, Nestor, Steinberg, Sinyor, Schaffer)
| | - Jasmine Amini
- Department of Psychiatry, Sunnybrook Health Sciences Centre, and Sunnybrook Research Institute, Toronto (all authors); Department of Psychiatry, University of Toronto, Toronto (Izadi, Mitchell, Giacobbe, Nestor, Steinberg, Sinyor, Schaffer)
| | - Mark Sinyor
- Department of Psychiatry, Sunnybrook Health Sciences Centre, and Sunnybrook Research Institute, Toronto (all authors); Department of Psychiatry, University of Toronto, Toronto (Izadi, Mitchell, Giacobbe, Nestor, Steinberg, Sinyor, Schaffer)
| | - Ayal Schaffer
- Department of Psychiatry, Sunnybrook Health Sciences Centre, and Sunnybrook Research Institute, Toronto (all authors); Department of Psychiatry, University of Toronto, Toronto (Izadi, Mitchell, Giacobbe, Nestor, Steinberg, Sinyor, Schaffer)
| |
Collapse
|
7
|
Toma S, Sinyor M, Mitchell RHB, Schaffer A. Transdiagnostic suicidality in depression: More similar than different? Acta Psychiatr Scand 2023; 148:219-221. [PMID: 37605854 DOI: 10.1111/acps.13600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Accepted: 07/23/2023] [Indexed: 08/23/2023]
Affiliation(s)
- Simina Toma
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Mark Sinyor
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Rachel H B Mitchell
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Ayal Schaffer
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
8
|
Yatham LN, Arumugham SS, Kesavan M, Ramachandran K, Murthy NS, Saraf G, Ouyang Y, Bond DJ, Schaffer A, Ravindran A, Ravindran N, Frey BN, Daigneault A, Beaulieu S, Lam RW, Kondapuram N, Reddy MS, Bhandary RP, Ashok MV, Ha K, Ahn YM, Milev R, Wong H, Reddy YCJ. Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression. N Engl J Med 2023; 389:430-440. [PMID: 37530824 DOI: 10.1056/nejmoa2300184] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 08/03/2023]
Abstract
BACKGROUND Antidepressants are used to treat acute depression in patients with bipolar I disorder, but their effect as maintenance treatment after the remission of depression has not been well studied. METHODS We conducted a multisite, double-blind, randomized, placebo-controlled trial of maintenance of treatment with adjunctive escitalopram or bupropion XL as compared with discontinuation of antidepressant therapy in patients with bipolar I disorder who had recently had remission of a depressive episode. Patients were randomly assigned in a 1:1 ratio to continue treatment with antidepressants for 52 weeks after remission or to switch to placebo at 8 weeks. The primary outcome, assessed in a time-to-event analysis, was any mood episode, as defined by scores on scales measuring symptoms of hypomania or mania, depression, suicidality, and mood-episode severity; additional treatment or hospitalization for mood symptoms; or attempted or completed suicide. Key secondary outcomes included the time to an episode of mania or hypomania or depression. RESULTS Of 209 patients with bipolar I disorder who participated in an open-label treatment phase, 150 who had remission of depression were enrolled in the double-blind phase in addition to 27 patients who were enrolled directly. A total of 90 patients were assigned to continue treatment with the prescribed antidepressant for 52 weeks (52-week group) and 87 were assigned to switch to placebo at 8 weeks (8-week group). The trial was stopped before full recruitment was reached owing to slow recruitment and funding limitations. At 52 weeks, 28 of the patients in the 52-week group (31%) and 40 in the 8-week group (46%) had a primary-outcome event. The hazard ratio for time to any mood episode in the 52-week group relative to the 8-week group was 0.68 (95% confidence interval [CI], 0.43 to 1.10; P = 0.12 by log-rank test). A total of 11 patients in the 52-week group (12%) as compared with 5 patients in the 8-week group (6%) had mania or hypomania (hazard ratio, 2.28; 95% CI, 0.86 to 6.08), and 15 patients (17%) as compared with 35 patients (40%) had recurrence of depression (hazard ratio, 0.43; 95% CI, 0.25 to 0.75). The incidence of adverse events was similar in the two groups. CONCLUSIONS In a trial involving patients with bipolar I disorder and a recently remitted depressive episode, adjunctive treatment with escitalopram or bupropion XL that continued for 52 weeks did not show a significant benefit as compared with treatment for 8 weeks in preventing relapse of any mood episode. The trial was stopped early owing to slow recruitment and funding limitations. (Funded by the Canadian Institutes of Health Research; ClinicalTrials.gov number, NCT00958633.).
Collapse
Affiliation(s)
- Lakshmi N Yatham
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - Shyam Sundar Arumugham
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - Muralidharan Kesavan
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - Kanchana Ramachandran
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - Nithyananda S Murthy
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - Gayatri Saraf
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - Yongdong Ouyang
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - David J Bond
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - Ayal Schaffer
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - Arun Ravindran
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - Nisha Ravindran
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - Benicio N Frey
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - Andrée Daigneault
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - Serge Beaulieu
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - Raymond W Lam
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - Nithin Kondapuram
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - M S Reddy
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - R P Bhandary
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - Mysore V Ashok
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - Kyooseob Ha
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - Yong Min Ahn
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - Roumen Milev
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - Hubert Wong
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| | - Y C Janardhan Reddy
- From the Vancouver Hospital Department of Psychiatry (L.N.Y., G.S., R.W.L.) and the School of Population and Public Health (Y.O., H.W.), University of British Columbia, Vancouver, the Department of Psychiatry, University of Ottawa, Ottawa (G.S.), the Department of Psychiatry, Sunnybrook Health Sciences Centre (A.S.), and the Centre for Addiction and Mental Health (A.R., N.R.), University of Toronto, Toronto, St. Joseph's Healthcare, the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON (B.N.F.), Douglas Hospital, McGill University (A.D., S.B.), and Hôpital Sacré-Coeur, Université de Montréal (A.D.), Montreal, and the Department of Psychiatry, Queen's University, Providence Care, Kingston, ON (R.M.) - all in Canada; the National Institute of Mental Health and Neuro Sciences (S.S.A., M.K., K.R., N.S.M., N.K., Y.C.J.R.) and St. John's Hospital Research Institute (M.V.A.), Bangalore, ASHA Hospital, Hyderabad (M.S.R.), and Kasturba Medical College of Manipal, Manipal Academy of Higher Education, Manipal (R.P.B.) - all in India; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (D.J.B.); and Seoul National University Bundang Hospital, Seongnam (K.H.), and Seoul National University Hospital (SNUH), Seoul (Y.M.A.) - both in South Korea
| |
Collapse
|
9
|
Chow NLY, Tateishi N, Goldhar A, Zaheer R, Redelmeier DA, Cheung AH, Schaffer A, Sinyor M. Does knowledge have a half-life? An observational study analyzing the use of older citations in medical and scientific publications. BMJ Open 2023; 13:e072374. [PMID: 37217270 DOI: 10.1136/bmjopen-2023-072374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/24/2023] Open
Abstract
OBJECTIVES In the process of scientific progress, prior evidence is both relied on and supplanted by new discoveries. We use the term 'knowledge half-life' to refer to the phenomenon in which older knowledge is discounted in favour of newer research. By quantifying the knowledge half-life, we sought to determine whether research published in more recent years is preferentially cited over older research in medical and scientific articles. DESIGN An observational study employing a directed, systematic search of current literature. DATA SOURCES BMJ, PNAS, JAMA, NEJM, The Annals of Internal Medicine, The Lancet, Science and Nature were searched. ELIGIBILITY CRITERIA FOR SELECTING STUDIES Eight high-impact medical and scientific journals were sampled examining original research articles from the first issue of every year over a 25-year span (1996-2020). The outcome of interest was the difference between the publication year of the article and references cited, termed 'citation lag'. DATA EXTRACTION AND SYNTHESIS Analysis of variance was used to identify significant differences in citation lag. RESULTS A total of 726 articles and 17 895 references were included with a mean citation lag of 7.5±8.4 years. Across all journals, >70% of references had been published within 10 years of the citing article. Approximately 15%-20% of referenced articles were 10-19 years old, and articles more than 20 years old were cited infrequently. Medical journals articles had references with significantly shorter citation lags compared with general science journals (p≤0.01). Articles published before 2009 had references with significantly shorter citation lags compared with those published in 2010-2020 (p<0.001). CONCLUSIONS This study found evidence of a small increase in the citation of older research in medical and scientific literature over the past decade. This phenomenon deserves further characterisation and scrutiny to ensure that 'old knowledge' is not being lost.
Collapse
Affiliation(s)
- Natalie L Y Chow
- Department of Anatomy and Cell Biology, Western University, London, Ontario, Canada
| | - Natalie Tateishi
- Department of Microbiology and Immunology, Western University, London, Ontario, Canada
| | - Alexa Goldhar
- Department of Biology, Queen's University, Kingston, Ontario, Canada
| | - Rabia Zaheer
- Department of Education Services, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
| | - Donald A Redelmeier
- Department of Medicine, University of Toronto Faculty of Medicine, Toronto, Ontario, Canada
- Department of Evaluative Clinical Sciences, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Amy H Cheung
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Ayal Schaffer
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Mark Sinyor
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
10
|
Hawley LL, Niederkrotenthaler T, Zaheer R, Schaffer A, Redelmeier DA, Levitt AJ, Sareen J, Pirkis J, Sinyor M. Is the narrative the message? The relationship between suicide-related narratives in media reports and subsequent suicides. Aust N Z J Psychiatry 2023; 57:758-766. [PMID: 35999688 PMCID: PMC10126449 DOI: 10.1177/00048674221117072] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVES When journalists report on the details of a suicide, the way that they contextualize the meaning of the event (i.e. the 'narrative') can have significant consequences for readers. The 'Werther' and 'Papageno' narrative effects refer to increases and decreases in suicides across populations following media reports on suicidal acts or mastery of crises, respectively. The goal of this study was to investigate the impact of these different narrative constructs on subsequent suicides. METHODS This study examined the change in suicide counts over time in Toronto, Canada. It used latent difference score analysis, examining suicide-related print media reports in the Toronto media market (2011-2014). Articles (N = 6367) were coded as having a potentially harmful narrative if they described suicide in a celebrity or described a suicide death in a non-celebrity and included the suicide method. Articles were coded as having potentially protective narratives if they included at least one element of protective content (e.g. alternatives to suicide) without including any information about suicidal behaviour (i.e. suicide attempts or death). RESULTS Latent difference score longitudinal multigroup analyses identified a dose-response relationship in which the trajectory of suicides following harmful 'Werther' narrative reports increased over time, while protective 'Papageno' narrative reports declined. The latent difference score model demonstrated significant goodness of fit and parameter estimates, with each group demonstrating different trajectories of change in reported suicides over time: (χ2[6], N = 6367) = 13.16; χ2/df = 2.19; Akaike information criterion = 97.16, comparative fit index = 0.96, root mean square error of approximation = 0.03. CONCLUSION Our findings support the notion that the 'narrative' matters when reporting on suicide. Specifically, 'Werther' narratives of suicides in celebrities and suicides in non-celebrities where the methods were described were associated with more subsequent suicides while 'Papageno' narratives of survival and crisis mastery without depictions of suicidal behaviours were associated with fewer subsequent suicides. These results may inform efforts to prevent imitation suicides.
Collapse
Affiliation(s)
- Lance L Hawley
- Frederick W. Thompson Anxiety Disorders
Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
- Department of Psychiatry, Sunnybrook Health
Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - Thomas Niederkrotenthaler
- Unit Suicide Research and Mental Health
Promotion, Department of Social and Preventive Medicine, Center for Public Health, Medical
University of Vienna, Vienna, Austria
| | - Rabia Zaheer
- Department of Psychiatry, Sunnybrook Health
Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - Ayal Schaffer
- Department of Psychiatry, Sunnybrook Health
Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - Donald A Redelmeier
- Department of Medicine, University of
Toronto, Toronto, ON, Canada
- Evaluative Clinical Sciences, Sunnybrook
Research Institute, Toronto, ON, Canada
- Division of General Internal Medicine,
Sunnybrook Health Sciences Centre, Toronto, ON, Canada
- Institute for Clinical Evaluative Sciences,
Toronto, ON, Canada
| | - Anthony J Levitt
- Department of Psychiatry, Sunnybrook Health
Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - Jitender Sareen
- Departments of Psychiatry, Psychology and
Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada
| | - Jane Pirkis
- Centre for Mental Health, Melbourne School of
Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia
| | - Mark Sinyor
- Department of Psychiatry, Sunnybrook Health
Sciences Centre, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
11
|
Tourjman SV, Buck G, Jutras-Aswad D, Khullar A, McInerney S, Saraf G, Pinto JV, Potvin S, Poulin MJ, Frey BN, Kennedy SH, Lam RW, MacQueen G, Milev R, Parikh SV, Ravindran A, McIntyre RS, Schaffer A, Taylor VH, van Ameringen M, Yatham LN, Beaulieu S. Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder. Can J Psychiatry 2023; 68:299-311. [PMID: 35711159 PMCID: PMC10192829 DOI: 10.1177/07067437221099769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Given the increasing acceptability and legalization of cannabis in some jurisdictions, clinicians need to improve their understanding of the effect of cannabis use on mood disorders. OBJECTIVE The purpose of this task force report is to examine the association between cannabis use and incidence, presentation, course and treatment of bipolar disorder and major depressive disorder, and the treatment of comorbid cannabis use disorder. METHODS We conducted a systematic literature review using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, searching PubMed, Embase, PsycINFO, CINAHL and Cochrane Central Register of Controlled Trials from inception to October 2020 focusing on cannabis use and bipolar disorder or major depressive disorder, and treatment of comorbid cannabis use disorder. The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach was used to evaluate the quality of evidence and clinical considerations were integrated to generate Canadian Network for Mood and Anxiety Treatments recommendations. RESULTS Of 12,691 publications, 56 met the criteria: 23 on bipolar disorder, 21 on major depressive disorder, 11 on both diagnoses and 1 on treatment of comorbid cannabis use disorder and major depressive disorder. Of 2,479,640 participants, 12,502 were comparison participants, 73,891 had bipolar disorder and 408,223 major depressive disorder without cannabis use. Of those with cannabis use, 2,761 had bipolar disorder and 5,044 major depressive disorder. The lifetime prevalence of cannabis use was 52%-71% and 6%-50% in bipolar disorder and major depressive disorder, respectively. Cannabis use was associated with worsening course and symptoms of both mood disorders, with more consistent associations in bipolar disorder than major depressive disorder: increased severity of depressive, manic and psychotic symptoms in bipolar disorder and depressive symptoms in major depressive disorder. Cannabis use was associated with increased suicidality and decreased functioning in both bipolar disorder and major depressive disorder. Treatment of comorbid cannabis use disorder and major depressive disorder did not show significant results. CONCLUSION The data indicate that cannabis use is associated with worsened course and functioning of bipolar disorder and major depressive disorder. Future studies should include more accurate determinations of type, amount and frequency of cannabis use and select comparison groups which allow to control for underlying common factors.
Collapse
Affiliation(s)
- Smadar V. Tourjman
- Department of Psychiatry and Addiction, Université de Montréal, Montreal, Quebec, Canada
- Research Center, Institut Universitaire en Santé Mentale de Montréal, Montreal, Quebec, Canada
| | - Gabriella Buck
- Bipolar Disorders Clinic, Douglas Mental Health University Institute, Montreal, Quebec, Canada
| | - Didier Jutras-Aswad
- Department of Psychiatry and Addiction, Université de Montréal, Montreal, Quebec, Canada
| | - Atul Khullar
- Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada
| | - Shane McInerney
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Gayatri Saraf
- Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada
| | - Jairo V. Pinto
- Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada
| | - Stephane Potvin
- Department of Psychiatry and Addiction, Université de Montréal, Montreal, Quebec, Canada
| | | | - Benicio N. Frey
- Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada
| | - Sidney H. Kennedy
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Raymond W. Lam
- Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada
| | - Glenda MacQueen
- Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada
| | - Roumen Milev
- Department of Psychiatry, Queen’s University, Kingston, Ontario, Canada
| | - Sagar V. Parikh
- Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA
| | - Arun Ravindran
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Roger S. McIntyre
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Ayal Schaffer
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Valerie H. Taylor
- Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada
| | - Michael van Ameringen
- Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada
| | - Lakshmi N. Yatham
- Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada
| | - Serge Beaulieu
- Department of Psychiatry, McGill University, Montreal, Quebec, Canada
| |
Collapse
|
12
|
Holman S, Steinberg R, Sinyor M, Lane H, Starritt K, Kennedy SH, Niederkrotenthaler T, Zaretsky A, Castel S, Schaffer A. Caring Contacts to Reduce Psychiatric Morbidity Following Hospitalization During the COVID-19 Pandemic: A Pilot Randomized Controlled Trial. Can J Psychiatry 2023; 68:152-162. [PMID: 35996823 PMCID: PMC9412148 DOI: 10.1177/07067437221121111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVES Caring Contacts are an emerging intervention that aims to reduce distress and suicide risk after acute psychiatric care. This trial aimed to determine whether, during a pandemic, there was any evidence that the mental health benefits and reduction in suicidal ideation (SI) associated with delivering Caring Contacts to recently discharged psychiatric patients were greater than a control communication. The secondary objective was to identify whether the predicted benefits were greater among people living alone or those diagnosed with depression. METHOD A single-site pilot randomized clinical trial (n = 100), with patients recruited from the adult Inpatient Psychiatry Unit at Sunnybrook Health Sciences Centre, Toronto, Canada between August 2020 and May 2021. Participants were randomized (1:1) to the Caring Contact or control group. Participants received three Caring Contact or control communications via email or mail (on days 4, 21, and 56 post-discharge). Mental health symptoms were assessed using the self-report Hopkins Symptom Checklist-25 (HSCL-25) scores at discharge (baseline) and when participants received each communication. Analysis of variance was used for the primary comparisons and exploratory analyses for subgroups. RESULTS Both groups experienced a significant worsening of mental health symptoms at all time points post-discharge relative to baseline. There were no significant differences between groups at any time point, however, on day 4 there was a 24.2% and 72.6% attenuated worsening in the Caring Contact group compared to the control group for total symptom severity and SI, respectively. There was no significant interaction effect for the depression subgroup or those living alone. CONCLUSIONS While this pilot study was not powered to identify significant differences between groups, results are indicative of feasibility and acceptability of the intervention and provide some indication that Caring Contacts may have benefited patients in the days following discharge, supporting the need for larger-scale trials. The study was registered with clinicaltrials.gov (study ID NCT04456062).
Collapse
Affiliation(s)
- Sarah Holman
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Rosalie Steinberg
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, 7938University of Toronto, Toronto, Ontario, Canada
| | - Mark Sinyor
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, 7938University of Toronto, Toronto, Ontario, Canada
| | - Hillary Lane
- Department of Psychiatry Patient and Family Advisory Council, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Kaleigh Starritt
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Sidney H Kennedy
- Department of Psychiatry, 7938University of Toronto, Toronto, Ontario, Canada.,10071Department of Psychiatry, St. Michael's Hospital, Toronto, Ontario, Canada
| | | | - Ari Zaretsky
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, 7938University of Toronto, Toronto, Ontario, Canada
| | - Saulo Castel
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, 7938University of Toronto, Toronto, Ontario, Canada
| | - Ayal Schaffer
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, 7938University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
13
|
Khoubaeva D, Dimick M, Timmins VH, Fiksenbaum LM, Mitchell RHB, Schaffer A, Sinyor M, Goldstein BI. Clinical correlates of suicidality and self-injurious behaviour among Canadian adolescents with bipolar disorder. Eur Child Adolesc Psychiatry 2023; 32:41-51. [PMID: 34028609 DOI: 10.1007/s00787-021-01803-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/21/2020] [Accepted: 05/09/2021] [Indexed: 11/26/2022]
Abstract
There is high risk of suicidality in bipolar disorder (BD), particularly in early onset cases. The literature regarding correlates and putative predictors of suicide attempts (SA), non-suicidal self-injury (NSSI) and suicidal ideation (SI) among youth with BD remains sparse. Participants included 197 adolescents with BD, divided into 4 groups: SA (with or without NSSI), NSSI (with or without SI), SI only, and comparison group (CG; no SA/NSSI/SI). Diagnoses, treatment, and suicidality measures were determined via semi-structured interviews, conducted between 2009 and 2017. Univariate analyses were followed by multinomial regression. Overall, 73.6% of participants had history of SA, NSSI, and/or SI. In comparison to CG, SA and NSSI were each associated with BD-II/-NOS (odds ratio [OR] = 15.99, p = 0.002; OR = 16.76, p = 0.003), female sex (OR = 6.89, p = 0.006; OR = 3.76, p = 0.02), and emotion dysregulation (OR = 1.10, p < 0.001; OR = 1.07, p = 0.004). NSSI and SI were each associated with most severe lifetime depression (OR = 1.10, p = 0.01; OR = 1.10, p = 0.01). SA and SI were associated with psychiatric hospitalization (OR = 19.45, p = 0.001; OR = 6.09, p = 0.03). SA was associated with poorer global functioning at most severe episode (OR = 0.88, p = 0.008). NSSI was associated with not living with both natural parents (OR = 0.22, p = 0.009). Study limitations include cross-sectional and retrospective design, stringent cut-offs for SA and NSSI, and recruitment from a tertiary clinical setting. Three quarters of adolescents with BD have had suicidality and/or self-injury. SA and NSSI were most similar to one another, and most different from CG, supporting the broader construct of self-harm. Future research should address the gap in knowledge regarding how sex differences and neurobiology are associated with the observed clinical differences.
Collapse
Affiliation(s)
- Diana Khoubaeva
- Centre for Youth Bipolar Disorder, Centre for Addiction and Mental Health, 80 Workman Way, Toronto, ON, M6J 1H4, Canada
| | - Mikaela Dimick
- Centre for Youth Bipolar Disorder, Centre for Addiction and Mental Health, 80 Workman Way, Toronto, ON, M6J 1H4, Canada
- Department of Pharmacology, University of Toronto, Toronto, ON, Canada
| | - Vanessa H Timmins
- Centre for Youth Bipolar Disorder, Centre for Addiction and Mental Health, 80 Workman Way, Toronto, ON, M6J 1H4, Canada
| | | | - Rachel H B Mitchell
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - Ayal Schaffer
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - Mark Sinyor
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - Benjamin I Goldstein
- Centre for Youth Bipolar Disorder, Centre for Addiction and Mental Health, 80 Workman Way, Toronto, ON, M6J 1H4, Canada.
- Department of Pharmacology, University of Toronto, Toronto, ON, Canada.
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
| |
Collapse
|
14
|
Rosenblat JD, Husain MI, Lee Y, McIntyre RS, Mansur RB, Castle D, Offman H, Parikh SV, Frey BN, Schaffer A, Greenway KT, Garel N, Beaulieu S, Kennedy SH, Lam RW, Milev R, Ravindran AV, Tourjman V, Ameringen MV, Yatham LN, Taylor V. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder. Can J Psychiatry 2023; 68:5-21. [PMID: 35975555 PMCID: PMC9720483 DOI: 10.1177/07067437221111371] [Citation(s) in RCA: 14] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
OBJECTIVE Serotonergic psychedelics are re-emerging as potential novel treatments for several psychiatric disorders including major depressive disorder. The Canadian Network for Mood and Anxiety Treatments (CANMAT) convened a task force to review the evidence and provide a consensus recommendation for the clinical use of psychedelic treatments for major depressive disorder. METHODS A systematic review was conducted to identify contemporary clinical trials of serotonergic psychedelics for the treatment of major depressive disorder and cancer-related depression. Studies published between January 1990 and July 2021 were identified using combinations of search terms, inspection of bibliographies and review of other psychedelic reviews and consensus statements. The levels of evidence for efficacy were graded according to the Canadian Network for Mood and Anxiety Treatments criteria. RESULTS Only psilocybin and ayahuasca have contemporary clinical trials evaluating antidepressant effects. Two pilot studies showed preliminary positive effects of single-dose ayahuasca for treatment-resistant depression (Level 3 evidence). Small randomized controlled trials of psilocybin combined with psychotherapy showed superiority to waitlist controls and comparable efficacy and safety to an active comparator (escitalopram with supportive psychotherapy) in major depressive disorder, with additional randomized controlled trials showing efficacy specifically in cancer-related depression (Level 3 evidence). There was only one open-label trial of psilocybin in treatment-resistant unipolar depression (Level 4 evidence). Small sample sizes and functional unblinding were major limitations in all studies. Adverse events associated with psychedelics, including psychological (e.g., psychotomimetic effects) and physical (e.g., nausea, emesis and headaches) effects, were generally transient. CONCLUSIONS There is currently only low-level evidence to support the efficacy and safety of psychedelics for major depressive disorder. In Canada, as of 2022, psilocybin remains an experimental option that is only available through clinical trials or the special access program. As such, Canadian Network for Mood and Anxiety Treatments considers psilocybin an experimental treatment and recommends its use primarily within clinical trials, or, less commonly, through the special access program in rare, special circumstances.
Collapse
Affiliation(s)
- Joshua D Rosenblat
- Department of Psychiatry, 7938University of Toronto, Toronto, Ontario, Canada.,7978Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
| | - M Ishrat Husain
- Department of Psychiatry, 7938University of Toronto, Toronto, Ontario, Canada.,Centre for Addiction and Mental Health, Campbell Family Mental Health Research Institute Toronto, Ontario, Canada
| | - Yena Lee
- 7978Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
| | - Roger S McIntyre
- Department of Psychiatry, 7938University of Toronto, Toronto, Ontario, Canada.,7978Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
| | - Rodrigo B Mansur
- Department of Psychiatry, 7938University of Toronto, Toronto, Ontario, Canada.,7978Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
| | - David Castle
- Department of Psychiatry, 7938University of Toronto, Toronto, Ontario, Canada.,Centre for Addiction and Mental Health, Campbell Family Mental Health Research Institute Toronto, Ontario, Canada
| | - Hilary Offman
- Department of Psychiatry, 7938University of Toronto, Toronto, Ontario, Canada
| | - Sagar V Parikh
- Department of Psychiatry, 7938University of Toronto, Toronto, Ontario, Canada.,Depression Program, Michigan Medicine, University of Michigan, Ann Arbor, USA
| | - Benicio N Frey
- Mood Disorders Program, St. Joseph's Healthcare Hamilton, McMaster University, Psychiatry & Behavioural Neurosciences, Hamilton, Ontario, Canada
| | - Ayal Schaffer
- Department of Psychiatry, 7938University of Toronto, Toronto, Ontario, Canada.,Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | | | - Nicolas Garel
- McGill University, Psychiatry, Montreal, Quebec, Canada
| | | | - Sidney H Kennedy
- Department of Psychiatry, 7938University of Toronto, Toronto, Ontario, Canada.,7978Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
| | - Raymond W Lam
- Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada
| | - Roumen Milev
- Department of Psychiatry, Providence Care, Queen's University, Kingston, ON, Canada
| | - Arun V Ravindran
- Department of Psychiatry, 7938University of Toronto, Toronto, Ontario, Canada.,Centre for Addiction and Mental Health, Campbell Family Mental Health Research Institute Toronto, Ontario, Canada
| | - Valerie Tourjman
- Institut universitaire en santé mentale de Montréal, Psychiatry, Montreal, Quebec, Canada
| | - Michael Van Ameringen
- McMaster University Medical Centre, Anxiety Disorders Clinic, Hamilton, Ontario, Canada
| | - Lakshmi N Yatham
- Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada
| | - Valerie Taylor
- Department of Psychiatry, 7938University of Toronto, Toronto, Ontario, Canada.,7978Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
| |
Collapse
|
15
|
Holman S, Steinberg R, Schaffer A, Fiksenbaum L, Sinyor M. The association of social, economic, and health-related variables with suicidal and/or self-harm thoughts in individuals admitted to a psychiatric inpatient unit during the COVID-19 pandemic: An exploratory study. Psychiatry Res 2023; 319:114998. [PMID: 36535108 PMCID: PMC9737504 DOI: 10.1016/j.psychres.2022.114998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/05/2022] [Revised: 07/28/2022] [Accepted: 12/02/2022] [Indexed: 12/14/2022]
Abstract
Individuals with pre-existing psychiatric diagnoses appear to be vulnerable to worsening mental health symptoms during the coronavirus disease 2019 (COVID-19) pandemic. Furthermore, psychiatric hospitalizations during the pandemic may be complicated by increased risk of SARS-Cov-2 infection and limited social engagement due to changes in hospital policies. The objective of our exploratory study was to determine whether social, economic, and health-related variables were associated with thoughts of suicide and/or self-harm since March 2020 in individuals admitted to a psychiatric inpatient unit during the COVID-19 pandemic. Chi-square tests revealed four variables were significantly associated with thoughts of suicide and/or self-harm: 1) difficulty with cancellation of important events, 2) some form of loneliness, 3) decreased time spent in green spaces, and 4) increased time spent using devices with screens. The logistic regression model showed a significant association between suicidal and/or self-harm thoughts and cancellation of important events. Further investigation of the loneliness variable components revealed a significant association between suicidal and/or self-harm thoughts and feeling a lack of companionship, feeling isolated, and feeling alone. These results suggest that social challenges experienced during the pandemic were associated with negative mental health symptoms of individuals admitted to a psychiatric inpatient unit.
Collapse
Affiliation(s)
- Sarah Holman
- Department of Psychiatry, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada
| | - Rosalie Steinberg
- Department of Psychiatry, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada,Department of Psychiatry, University of Toronto, 27 King's College Cir, Toronto, ON M5S 1A1, Canada
| | - Ayal Schaffer
- Department of Psychiatry, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada,Department of Psychiatry, University of Toronto, 27 King's College Cir, Toronto, ON M5S 1A1, Canada
| | - Lisa Fiksenbaum
- Department of Psychology, York University, 4700 Keele St, Toronto, ON M3J 1P3, Canada
| | - Mark Sinyor
- Department of Psychiatry, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada; Department of Psychiatry, University of Toronto, 27 King's College Cir, Toronto, ON M5S 1A1, Canada.
| |
Collapse
|
16
|
Gordon M, Jayakumar N, Schaffer D, Vije M, Schaffer A, Niederkrotenthaler T, Pirkis J, Sinyor M. An Observational Study of Suicide-Related Media Reports During the Early Months of the Coronavirus Disease 2019 Pandemic in Canada. Can J Psychiatry 2023; 68:64-66. [PMID: 36124382 PMCID: PMC9486677 DOI: 10.1177/07067437221125316] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- Madeleine Gordon
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Temerty Faculty of Medicine, Institute of Medical Science, 7938University of Toronto, Toronto, Ontario, Canada
| | - Navitha Jayakumar
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Dalia Schaffer
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,5620McGill University, Montreal, Quebec, Canada
| | - Mathavan Vije
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,6221The University of Western Ontario, London, Ontario, Canada
| | - Ayal Schaffer
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, 7938University of Toronto, Toronto, Ontario, Canada
| | - Thomas Niederkrotenthaler
- Center for Public Health, Department of Social and Preventive Medicine, Unit Suicide Research & Mental Health Promotion, Medical University of Vienna, Vienna, Austria
| | - Jane Pirkis
- Centre for Mental Health, Melbourne School of Population and Global Health, The University of Melbourne, Carlton, Victoria, Australia
| | - Mark Sinyor
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Temerty Faculty of Medicine, Institute of Medical Science, 7938University of Toronto, Toronto, Ontario, Canada.,Department of Psychiatry, 7938University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
17
|
Kim WSH, Dimick MK, Omrin D, Mitchell RHB, Riegert D, Levitt A, Schaffer A, Belo S, Iazzetta J, Detzler G, Choi M, Choi S, Herrmann N, McIntyre RS, MacIntosh BJ, Orser BA, Goldstein BI. Proof-of-concept randomized controlled trial of single-session nitrous oxide treatment for refractory bipolar depression: Focus on cerebrovascular target engagement. Bipolar Disord 2022; 25:221-232. [PMID: 36579458 DOI: 10.1111/bdi.13288] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
BACKGROUND There remain few efficacious treatments for bipolar depression, which dominates the course of bipolar disorder (BD). Despite multiple studies reporting associations between depression and cerebral blood flow (CBF), little is known regarding CBF as a treatment target, or predictor and/or indicator of treatment response, in BD. Nitrous oxide, an anesthetic gas with vasoactive and putative antidepressant properties, has a long history as a neuroimaging probe. We undertook an experimental medicine paradigm, coupling in-scanner single-session nitrous oxide treatment of bipolar depression with repeated measures of CBF. METHODS In this double-blind randomized controlled trial, 25 adults with BD I/II and current treatment-refractory depression received either: (1) nitrous oxide (20 min at 25% concentration) plus intravenous saline (n = 12), or (2) medical air plus intravenous midazolam (2 mg total; n = 13). Study outcomes included changes in depression severity (Montgomery-Asberg Depression Rating Scale scores, primary) and changes in CBF (via arterial spin labeling magnetic resonance imaging). RESULTS There were no significant between-group differences in 24-h post-treatment MADRS change or treatment response. However, the nitrous oxide group had significantly greater same-day reductions in depression severity. Lower baseline regional CBF predicted greater 24-h post-treatment MADRS reductions with nitrous oxide but not midazolam. In region-of-interest and voxel-wise analyses, there was a pattern of regional CBF reductions following treatment with midazolam versus nitrous oxide. CONCLUSIONS Present findings, while tentative and based on secondary endpoints, suggest differential associations of nitrous oxide versus midazolam with bipolar depression severity and cerebral hemodynamics. Larger studies integrating neuroimaging targets and repeated nitrous oxide treatment sessions are warranted.
Collapse
Affiliation(s)
- William S H Kim
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.,Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada
| | - Mikaela K Dimick
- Centre for Youth Bipolar Disorder, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.,Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada
| | - Danielle Omrin
- Centre for Youth Bipolar Disorder, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.,Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Rachel H B Mitchell
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.,Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Daniel Riegert
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada
| | - Anthony Levitt
- Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.,Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Ayal Schaffer
- Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.,Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Susan Belo
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada
| | - John Iazzetta
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | | | - Mabel Choi
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada
| | - Stephen Choi
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada
| | - Nathan Herrmann
- Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.,Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Roger S McIntyre
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.,Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.,Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
| | - Bradley J MacIntosh
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.,Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada
| | - Beverley A Orser
- Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.,Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada
| | - Benjamin I Goldstein
- Centre for Youth Bipolar Disorder, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.,Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.,Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
18
|
Sinyor M, Mallia E, de Oliveira C, Schaffer A, Niederkrotenthaler T, Zaheer J, Mitchell R, Rudoler D, Kurdyak P. Emergency department visits for self-harm in adolescents after
release of the Netflix series ‘13 Reasons Why’. Aust N Z J Psychiatry 2022; 56:1434-1442. [PMID: 34963338 PMCID: PMC9597162 DOI: 10.1177/00048674211065999] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
OBJECTIVE To determine whether the release of the first season of the Netflix series '13 Reasons Why' was associated with changes in emergency department presentations for self-harm. METHODS Healthcare utilization databases were used to identify emergency department and outpatient presentations according to age and sex for residents of Ontario, Canada. Data from 2007 to 2018 were used in autoregressive integrated moving average models for time series forecasting with a pre-specified hypothesis that rates of emergency department presentations for self-harm would increase in the 3-month period following the release of 13 Reasons Why (1 April 2017 to 30 June 2017). Chi-square and t tests were used to identify demographic and health service use differences between those presenting to emergency department with self-harm during this epoch compared to a control period (1 April 2016 to 30 June 2016). RESULTS There was a significant estimated excess of 75 self-harm-related emergency department visits (+6.4%) in the 3 months after 13 Reasons Why above what was predicted by the autoregressive integrated moving average model (standard error = 32.4; p = 0.02); adolescents aged 10-19 years had 60 excess visits (standard error = 30.7; p = 0.048), whereas adults demonstrated no significant change. Sex-stratified analyses demonstrated that these findings were largely driven by significant increases in females. There were no differences in demographic or health service use characteristics between those who presented to emergency department with self-harm in April to June 2017 vs April to June 2016. CONCLUSIONS This study demonstrated a significant increase in self-harm emergency department visits associated with the release of 13 Reasons Why. It adds to previously published mortality, survey and helpline data collectively demonstrating negative mental health outcomes associated with 13 Reasons Why.
Collapse
Affiliation(s)
- Mark Sinyor
- Department of Psychiatry, Sunnybrook
Health Sciences Centre, Toronto, ON, Canada,Department of Psychiatry, University of
Toronto, Toronto, ON, Canada,Mark Sinyor, Department of Psychiatry,
Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, FG52, Toronto, ON M4N
3M5, Canada.
| | - Emilie Mallia
- Institute for Mental Health Policy
Research, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada
| | - Claire de Oliveira
- Institute for Mental Health Policy
Research, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada,Centre for Health Economics and Hull
York Medical School, University of York, York, UK,ICES, Toronto, ON, Canada,Institute of Health Policy, Management
and Evaluation, University of Toronto, Toronto, ON, Canada
| | - Ayal Schaffer
- Department of Psychiatry, Sunnybrook
Health Sciences Centre, Toronto, ON, Canada,Department of Psychiatry, University of
Toronto, Toronto, ON, Canada
| | - Thomas Niederkrotenthaler
- Unit Suicide Research & Mental
Health Promotion, Department of Social and Preventive Medicine, Center for Public
Health, Medical University of Vienna, Vienna, Austria
| | - Juveria Zaheer
- Department of Psychiatry, University of
Toronto, Toronto, ON, Canada,General and Health Systems Psychiatry,
Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada
| | - Rachel Mitchell
- Department of Psychiatry, Sunnybrook
Health Sciences Centre, Toronto, ON, Canada,Department of Psychiatry, University of
Toronto, Toronto, ON, Canada
| | - David Rudoler
- ICES, Toronto, ON, Canada,Institute of Health Policy, Management
and Evaluation, University of Toronto, Toronto, ON, Canada,Faculty of Health Sciences, Ontario
Tech University, Oshawa, ON, Canada
| | - Paul Kurdyak
- Department of Psychiatry, University of
Toronto, Toronto, ON, Canada,Institute for Mental Health Policy
Research, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada,ICES, Toronto, ON, Canada,Institute of Health Policy, Management
and Evaluation, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
19
|
Hatcher S, Heisel MJ, Ayonrinde O, Corsi D, Edgar NE, Kennedy SH, Rizvi SJ, Schaffer A, Sinyor M. The BEACON study: an update to the protocol for a cohort study as part of an evaluation of the effectiveness of smartphone-assisted problem-solving therapy in men who present with intentional self-harm to emergency departments in Ontario. Trials 2022; 23:849. [PMID: 36199120 PMCID: PMC9532822 DOI: 10.1186/s13063-022-06788-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2022] [Accepted: 09/25/2022] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Men who present to the emergency department (ED) with self-harm are at high risk of dying by suicide, with 2.7% of men dying in the year following their presentation, more than double the rate for women (1.2%). Despite this, care received after an ED visit is highly variable and many are not assessed for psychological needs. Furthermore, the limited psychological care that is available is often not covered by provincial health insurance. Even when referrals for follow-up care are made, engagement rates are low. Previous recommendations to improve engagement include written discharge plans, caring contacts, and focused interventions targeting middle-aged men at elevated risk of dying by suicide. Blended care, the incorporation of technology into traditional care, has also been proposed as a method to increase engagement in and clinical benefits from psychotherapy. This project aims to determine whether the delivery of an evidence based treatment (problem-solving therapy (PST)) is enhanced by the addition of a custom smartphone application (BEACON) compared to usual care. Due to the impact of the COVID-19 pandemic on site participation and the planned implementation, we have made several changes to the study design, primary outcome, and implementation. METHOD We originally proposed a cohort study nested within a larger cluster randomized trial wherein intervention sites would deliver the blended care, and control sites, whose personnel were not aware of their participation, would continue delivering usual care. The cohort study evaluated participant level outcomes as previously described by Hatcher et al. (2020). Due to pandemic-related constraints, our number of participating sites dropped to five potential sites which left the cohort study underpowered. As such, we changed the study design to a multi-site, individual randomized controlled trial (RCT) among the five remaining sites. Participants will be randomized to six sessions of therapy (PST) alone, or to the therapy plus BEACON, and followed up for 6 months. Our primary outcome was changed to evaluate feasibility and acceptability with the aim of designing a definitive RCT. Study implementation was reimagined to allow for completely virtual/online conduct to comply with local COVID-19 and institutional restrictions on in-person activities. CONCLUSION This updated protocol will provide strong results for the planning of a definitive RCT of the blended care intervention in the future, addressing areas of difficulty and concern prior to its implementation. We will evaluate the feasibility of the study intervention, assess recruitment and retention of participants, and address challenges with implementing the protocol. Lastly, we will evaluate the appropriateness of our primary outcome measure and accurately determine a sample size for a definitive RCT. TRIAL REGISTRATION ClinicalTrials.gov, NCT03473535 . Registered on March 22, 2018.
Collapse
Affiliation(s)
- Simon Hatcher
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON, Canada. .,Department of Psychiatry, University of Ottawa, 5457-1145 Carling Avenue, Ottawa, ON, Canada. .,Department of Mental Health, The Ottawa Hospital, 501 Smyth Road, Ottawa, ON, Canada.
| | - Marnin J Heisel
- Departments of Psychiatry and of Epidemiology and Biostatistics, Western University, Parkwood Institute, Mental Health Care Building, London, ON, F4-365, Canada.,Department of Psychiatry, Lawson Health Research Institute, University of Rochester Medical Center, Rochester, NY, USA
| | - Oydeji Ayonrinde
- Department of Psychiatry, Queen's University, 752 King Street West, Postal Bag 603, Kingston, ON, Canada.,Kingston Health Sciences Centre, 76 Stuart Street, Kingston, ON, Canada
| | - Daniel Corsi
- School of Epidemiology and Public Health, University of Ottawa, 600 Peter Morand Crescent, Ottawa, ON, Canada
| | - Nicole E Edgar
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON, Canada
| | - Sidney H Kennedy
- Centre for Depression & Suicide Studies, St. Michael's Hospital, 193 Yonge St. Suite 6-001A, Toronto, ON, Canada.,Department of Psychiatry, University of Toronto, 250 College Street, 8th floor, Toronto, ON, Canada.,Li Ka Shing Knowledge Institute, St. Michael's Hospital, 30 Bond Street, Toronto, ON, Canada
| | - Sakina J Rizvi
- Department of Psychiatry, University of Toronto, 250 College Street, 8th floor, Toronto, ON, Canada.,ASR Suicide and Depression Studies Unit, St. Michael's Hospital, 193 Yonge St, 6-009, Toronto, ON, Canada.,Institute of Medical Science, University of Toronto, 1 King's College Circle, Medical Sciences Building, Room 2374, Toronto, ON, Canada
| | - Ayal Schaffer
- Department of Psychiatry, University of Toronto, 250 College Street, 8th floor, Toronto, ON, Canada.,Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, ON, Canada
| | - Mark Sinyor
- Department of Psychiatry, University of Toronto, 250 College Street, 8th floor, Toronto, ON, Canada.,Department of Psychiatry, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, Canada
| |
Collapse
|
20
|
Klim-Conforti P, Levitt AJ, Cheung AH, Loureiro R, Fefergrad M, Schaffer A, Niederkrotenthaler T, Sinyor M, Zaheer J. Youth voices and experiences regarding a school-based cognitive behavioral therapy skills intervention: lessons for future engagement and adaptation. BMC Public Health 2022; 22:1709. [PMID: 36076231 PMCID: PMC9461107 DOI: 10.1186/s12889-022-14058-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Accepted: 08/22/2022] [Indexed: 11/26/2022] Open
Abstract
Background The Cognitive Behavioral Therapy Skills Intervention (or CBTSI) aims to build mental health literacy and knowledge, allowing youth to build resilience and improve mental health broadly. In Ontario, Canada, youth voice is scant and European studies have largely reported on youth factors supporting stigma reduction, help-seeking intentions and overall satisfaction with a given intervention. Process evaluations and implementation that underpin what youth require to embrace mental health literacy interventions, particularly those that embed key learning principles in the everyday curriculum, have not been broached. The goal of this study is to understand both barriers and facilitators to engagement with the CBTSI (an intervention novel in itself because of the combined mental health plus cognitive behavior therapy (CBT) skills principles embedded in literacy) and the resources and structures that students report requiring, to fully engage with such an intervention. Methods Student focus groups were conducted utilizing qualitative interviews that were analyzed thematically. Analysis was informed using principles of pragmatism and analyzed inductively using thematic analysis (Braun and Clarke, Qual Res Psychol 3:77–101, 2006), first looking at the whole and then coding for themes, within an interpretivist framework. Youth were in middle school (grade 7 and 8) in Toronto, Canada who had received the CBTSI. Face to face interview guides with iterative questioning were conducted in February of 2020, and these interviews were audio-recorded and professionally transcribed. Teachers randomly chose a subset of youth whose parents consented to the research to ensure ethno-racial similarity to classroom demographics. Results There were eight groups with sixty students who participated. Students were 12 to 14 years of age. Major themes were identified: maximizing the opportunities for involvement and self-determination created an atmosphere where confidence and self-compassion could flourish, signalling to the students that they understood and were able to deploy the strategies they were taught; students expressed that the intervention needs to be adapted to enhance personal dignity, respecting both individual wishes and goals in light of the variability in student reported mental health. A model explains the structures and adaptations required to maximize learning based on youth feedback. Interpretation Mental health literacy incorporating CBT is a promising population-based health promotion intervention. Future adaptations and implementation decisions regarding the CBTSI need to address the wishes and experiences of these youth. Youth voice in this study explored factors that prevent and promote the uptake of the key lessons within the context of existing variability in student mental health that is often found within the context of a regular classroom. The results should be used to adapt the CBTSI as it is disseminated more broadly.
Collapse
Affiliation(s)
- Paula Klim-Conforti
- Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, 1 King's College Circle, Medical Sciences Building, Toronto, Ontario, M5S 3H2, Canada. .,Member of the College of Psychologists of Ontario, Toronto, Ontario, Canada. .,Member of the College of Registered Psychotherapists of Ontario, Toronto, Ontario, Canada.
| | - Anthony J Levitt
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada.,Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Amy H Cheung
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada.,Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Raisa Loureiro
- Member of the College of Registered Psychotherapists of Ontario, Toronto, Ontario, Canada
| | - Mark Fefergrad
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada.,Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Ayal Schaffer
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada.,Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Thomas Niederkrotenthaler
- Unit Suicide Research and Mental Health Promotion, Department of Social and Preventive Medicine, Centre for Public Health, Medical University of Vienna, Kinderspitalgasse 15, A-1090, Vienna, Austria.,Wiener Werkstaette for Suicide Research, Vienna, Austria
| | - Mark Sinyor
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada.,Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Juveria Zaheer
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.,Institute for Medical Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
| |
Collapse
|
21
|
Miskowiak KW, Yalin N, Seeberg I, Burdick KE, Balanzá‐Martínez V, Bonnin CDM, Bowie CR, Carvalho AF, Dols A, Douglas K, Gallagher P, Hasler G, Kessing LV, Lafer B, Lewandowski KE, López‐Jaramillo C, Martinez‐Aran A, McIntyre RS, Porter RJ, Purdon SE, Schaffer A, Sumiyoshi T, Torres IJ, Van Rheenen TE, Yatham LN, Young AH, Vieta E, Stokes PRA. Can magnetic resonance imaging enhance the assessment of potential new treatments for cognitive impairment in mood disorders? A systematic review and position paper by the International Society for Bipolar Disorders Targeting Cognition Task Force. Bipolar Disord 2022; 24:615-636. [PMID: 35950925 PMCID: PMC9826389 DOI: 10.1111/bdi.13247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
BACKGROUND Developing treatments for cognitive impairment is key to improving the functioning of people with mood disorders. Neuroimaging may assist in identifying brain-based efficacy markers. This systematic review and position paper by the International Society for Bipolar Disorders Targeting Cognition Task Force examines the evidence from neuroimaging studies of pro-cognitive interventions. METHODS We included magnetic resonance imaging (MRI) studies of candidate interventions in people with mood disorders or healthy individuals, following the procedures of the Preferred Reporting Items for Systematic reviews and Meta-Analysis 2020 statement. Searches were conducted on PubMed/MEDLINE, PsycInfo, EMBASE, Cochrane Library, and Clinicaltrials.gov from inception to 30th April 2021. Two independent authors reviewed the studies using the National Heart, Lung, Blood Institutes of Health Quality Assessment Tool for Controlled Intervention Studies and the quality of neuroimaging methodology assessment checklist. RESULTS We identified 26 studies (N = 702). Six investigated cognitive remediation or pharmacological treatments in mood disorders (N = 190). In healthy individuals, 14 studies investigated pharmacological interventions (N = 319), 2 cognitive training (N = 73) and 4 neuromodulatory treatments (N = 120). Methodologies were mostly rated as 'fair'. 77% of studies investigated effects with task-based fMRI. Findings varied but most consistently involved treatment-associated cognitive control network (CCN) activity increases with cognitive improvements, or CCN activity decreases with no cognitive change, and increased functional connectivity. In mood disorders, treatment-related default mode network suppression occurred. CONCLUSIONS Modulation of CCN and DMN activity is a putative efficacy biomarker. Methodological recommendations are to pre-declare intended analyses and use task-based fMRI, paradigms probing the CCN, longitudinal assessments, mock scanning, and out-of-scanner tests.
Collapse
Affiliation(s)
- Kamilla W. Miskowiak
- Copenhagen Affective disorder Research Centre (CADIC), Psychiatric Centre CopenhagenCopenhagen University HospitalCopenhagenDenmark,Department of PsychologyUniversity of CopenhagenCopenhagenDenmark
| | - Nefize Yalin
- Department of Psychological MedicineInstitute of Psychiatry, Psychology and Neuroscience, King's College LondonLondonUK
| | - Ida Seeberg
- Copenhagen Affective disorder Research Centre (CADIC), Psychiatric Centre CopenhagenCopenhagen University HospitalCopenhagenDenmark
| | - Katherine E. Burdick
- Department of PsychiatryHarvard Medical SchoolBostonMassachusettsUSA,Department of PsychiatryBrigham and Women's HospitalBostonMassachusettsUSA
| | - Vicent Balanzá‐Martínez
- Teaching Unit of Psychiatry and Psychological Medicine, Department of MedicineUniversity of Valencia, CIBERSAMValenciaSpain
| | - Caterina del Mar Bonnin
- Clinical Institute of Neuroscience, Hospital ClinicUniversity of Barcelona, IDIBAPS, CIBERSAMBarcelonaSpain
| | | | - Andre F. Carvalho
- IMPACT Strategic Research Centre (Innovation in Mental and Physical Health and Clinical Treatment)Deakin UniversityGeelongVictoriaAustralia
| | - Annemieke Dols
- Department of Old Age Psychiatry, GGZ in Geest, Amsterdam UMC, location VUmc, Amsterdam NeuroscienceAmsterdam Public Health research instituteAmsterdamThe Netherlands
| | - Katie Douglas
- Department of Psychological MedicineUniversity of OtagoChristchurchNew Zealand
| | - Peter Gallagher
- Translational and Clinical Research Institute, Faculty of Medical SciencesNewcastle UniversityNewcastle‐upon‐TyneUK
| | - Gregor Hasler
- Psychiatry Research UnitUniversity of FribourgFribourgSwitzerland
| | - Lars V. Kessing
- Copenhagen Affective disorder Research Centre (CADIC), Psychiatric Centre CopenhagenCopenhagen University HospitalCopenhagenDenmark,Department of Clinical MedicineUniversity of CopenhagenCopenhagenDenmark
| | - Beny Lafer
- Bipolar Disorder Research Program, Institute of Psychiatry, Hospital das Clinicas, Faculdade de MedicinaUniversidade de São PauloSão PauloBrazil
| | - Kathryn E. Lewandowski
- Department of PsychiatryHarvard Medical SchoolBostonMassachusettsUSA,McLean HospitalSchizophrenia and Bipolar Disorder ProgramBelmontMassachusettsUSA
| | - Carlos López‐Jaramillo
- Research Group in Psychiatry, Department of PsychiatryUniversidad de AntioquiaMedellínColombia
| | - Anabel Martinez‐Aran
- Clinical Institute of Neuroscience, Hospital ClinicUniversity of Barcelona, IDIBAPS, CIBERSAMBarcelonaSpain
| | - Roger S. McIntyre
- Mood Disorders Psychopharmacology Unit, Brain and Cognition Discovery FoundationUniversity of TorontoTorontoCanada
| | - Richard J. Porter
- Department of Psychological MedicineUniversity of OtagoChristchurchNew Zealand
| | - Scot E. Purdon
- Department of PsychiatryUniversity of AlbertaEdmontonCanada
| | - Ayal Schaffer
- Department of PsychiatryUniversity of TorontoTorontoCanada
| | - Tomiki Sumiyoshi
- Department of Preventive Intervention for Psychiatric Disorders, National Institute of Mental HealthNational Center of Neurology and PsychiatryTokyoJapan
| | - Ivan J. Torres
- Department of PsychiatryUniversity of British ColumbiaVancouverCanada
| | - Tamsyn E. Van Rheenen
- Melbourne Neuropsychiatry Centre, Department of PsychiatryUniversity of MelbourneCarltonAustralia,Centre for Mental Health, Faculty of Health, Arts and DesignSwinburne UniversityHawthornAustralia
| | - Lakshmi N. Yatham
- Department of PsychiatryUniversity of British ColumbiaVancouverCanada
| | - Allan H. Young
- Department of Psychological MedicineInstitute of Psychiatry, Psychology and Neuroscience, King's College LondonLondonUK
| | - Eduard Vieta
- Clinical Institute of Neuroscience, Hospital ClinicUniversity of Barcelona, IDIBAPS, CIBERSAMBarcelonaSpain
| | - Paul R. A. Stokes
- Department of Psychological MedicineInstitute of Psychiatry, Psychology and Neuroscience, King's College LondonLondonUK
| |
Collapse
|
22
|
Vazquez G, Gutierrez G, Rosenblat J, Schaffer A, Swainson J, Karthikeyan G, Ravindran N, Lam RW, Do A, Giacobbe P, Hawken E, Milev R. Association of intranasal esketamine, a novel 'standard of care' treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice. BMJ Open 2022; 12:e060967. [PMID: 36581972 PMCID: PMC9438206 DOI: 10.1136/bmjopen-2022-060967] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
INTRODUCTION Esketamine is the S-enantiomer of racemic ketamine and has been approved by the Food and Drug Administration for the management of treatment resistant depression, demonstrating effective and long-lasting benefits. The objective of this observational study is to elucidate the association of intranasal (IN) esketamine with beneficial and negative outcomes in the management of treatment resistant major depressive disorder. METHODS AND ANALYSIS This is a multicentre prospective cohort observational study of naturalistic clinical practice. We expect to recruit 10 patients per research centre (6 centres, total 60 subjects). After approval to receive IN esketamine as part of their standard of care management of moderate to severe treatment resistant depression, patients will be invited to participate in this study. Association of esketamine treatment with outcomes in the management of depression will be assessed by measuring the severity of depression symptoms using the Montgomery-Åsberg Depression Rating Scale (MADRS), and tolerability by systematically tracking common side effects of ketamine treatment, dissociation using the simplified 6-Item Clinician Administered Dissociative Symptom Scale and potential for abuse using the Likeability and Craving Questionnaire (LCQ). Change in depressive symptoms (MADRS total scores) over time will be evaluated by within-subject repeated measures analysis of variance. We will calculate the relative risk associated with the beneficial (reduction in total scores for depression) outcomes, and the side effect and dropout rates (tolerability) of adding IN esketamine to patients' current pharmacological treatments. Covariate analysis will assess the impact of site and demographic variables on treatment outcomes. ETHICS AND DISSEMINATION Approval to perform this study was obtained through the Health Sciences Research Ethics Board at Queen's University. Findings will be shared among collaborators, through departmental meetings, presented on different academic venues and publishing our manuscript.
Collapse
Affiliation(s)
- Gustavo Vazquez
- Psychiatry, Queen's University Faculty of Health Sciences, Kingston, Ontario, Canada
| | - Gilmar Gutierrez
- School of Medicine, Queen's University Faculty of Health Sciences, Kingston, Ontario, Canada
| | | | - Ayal Schaffer
- Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Jennifer Swainson
- Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada
| | | | | | - Raymond W Lam
- Psychiatry, The University of British Columbia, Vancouver, British Columbia, Canada
| | - André Do
- Department of Psychiatry, The University of British Columbia, Vancouver, British Columbia, Canada
| | - Peter Giacobbe
- Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Emily Hawken
- Psychiatry, Queen's University Faculty of Health Sciences, Kingston, Ontario, Canada
| | - Roumen Milev
- Psychiatry, Queen's University Faculty of Health Sciences, Kingston, Ontario, Canada
| |
Collapse
|
23
|
Sinyor M, Hartman M, Zaheer R, Williams M, Pirkis J, Heisel MJ, Schaffer A, Redelmeier DA, Cheung AH, Kiss A, Niederkrotenthaler T. Differences in Suicide-Related Twitter Content According to User Influence. Crisis 2022. [PMID: 35656646 DOI: 10.1027/0227-5910/a000865] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Background: The content of suicide-specific social media posts may impact suicide rates, and putatively harmful and/or protective content may vary by the author's influence. Aims: This study sought to characterize how suicide-related Twitter content differs according to user influence. Method: Suicide-related tweets from July 1, 2015, to June 1, 2016, geolocated to Toronto, Canada, were collected and randomly selected for coding (n = 2,250) across low, medium, or high user influence levels (based on the number of followers, tweets, retweets, and posting frequency). Logistic regression was used to identify differences by user influence for various content variables. Results: Low- and medium-influence users typically tweeted about personal experiences with suicide and associations with mental health and shared morbid humor/flippant tweets. High-influence users tended to tweet about suicide clusters, suicide in youth, older adults, indigenous people, suicide attempts, and specific methods. Tweets across influence levels predominantly focused on suicide deaths, and few described suicidal ideation or included helpful content. Limitations: Social media data were from a single location and epoch. Conclusion: This study demonstrated more problematic content vis-à-vis safe suicide messaging in tweets by high-influence users and a paucity of protective content across all users. These results highlight the need for further research and potential intervention.
Collapse
Affiliation(s)
- Mark Sinyor
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.,Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - Maya Hartman
- Michael G. DeGroote School of Medicine, McMaster University, Waterloo Regional Campus, Kitchener, ON, Canada
| | - Rabia Zaheer
- Department of Education Services, Centre for Addiction and Mental Health, Toronto, ON, Canada
| | - Marissa Williams
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.,Athabasca University, Athabasca, AB, Canada
| | - Jane Pirkis
- Centre for Mental Health, Melbourne School of Population and Global Health, University of Melbourne, Parkville, VIC, Australia
| | - Marnin J Heisel
- Departments of Psychiatry and of Epidemiology & Biostatistics, The University of Western Ontario, London, ON, Canada
| | - Ayal Schaffer
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.,Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - Donald A Redelmeier
- Division of General Internal Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.,Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
| | - Amy H Cheung
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.,Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - Alex Kiss
- Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
| | - Thomas Niederkrotenthaler
- Medical University of Vienna, Center for Public Health, Department of Social and Preventive Medicine, Unit Suicide Research & Mental Health Promotion, Vienna, Austria
| |
Collapse
|
24
|
Kozicky JM, Schaffer A, Beaulieu S, McIntosh D, Yatham LN. Use of a point-of-care web-based application to enhance adherence to the CANMAT and ISBD 2018 guidelines for the management of bipolar disorder. Bipolar Disord 2022; 24:392-399. [PMID: 34599641 DOI: 10.1111/bdi.13136] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
OBJECTIVES While clinical guidelines exist for the management of bipolar disorder (BD), there are significant challenges to their widespread dissemination and implementation in clinical practice. The Canadian Network of Mood and Anxiety Treatment Improving Patient Care and Outcomes in the Treatment of Bipolar Disorder (C-IMPACT BD) web-based application was developed for use at the point-of-care to improve adherence to guidelines for evidence-based pharmacological management of BD. METHODS C-IMPACT BD uses a point-of-care practice assessment which, via adaptive questioning of patient-specific information, text/video descriptions of the guidelines, and pop-up prompts delivers personalized, evidence-based treatment recommendations for patients with BD. In order to inform quality improvement of the newly developed tool, a sample of Canadian physicians were invited to use the application and record its influence on their prescribing behavior. RESULTS Of 375 patients with bipolar I (BD-I) or bipolar II (BD-II) disorder for whom a point-of-care practice assessment was completed, a change in therapy was considered for 225 (60.0%). Prior to completing the assessment, 59.6% of these patients were receiving first-line therapy recommended for their phase of illness. Following the assessment, the overall number of patients for whom a first-line recommended therapy was being considered increased significantly to 76.9% (p = 0.0001). CONCLUSIONS Outcomes suggest that the C-IMPACT BD web-based application has the potential to improve physician adherence to clinical treatment guidelines. Formal research investigations are warranted to explore the impact of this tool on physician prescribing behavior and patient outcomes.
Collapse
Affiliation(s)
- Jan-Marie Kozicky
- School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
| | - Ayal Schaffer
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Serge Beaulieu
- Department of Psychiatry, McGill University, Montreal, Quebec, Canada
| | - Diane McIntosh
- Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada
| | - Lakshmi N Yatham
- Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada
| |
Collapse
|
25
|
Miskowiak KW, Seeberg I, Jensen MB, Balanzá‐Martínez V, del Mar Bonnin C, Bowie CR, Carvalho AF, Dols A, Douglas K, Gallagher P, Hasler G, Lafer B, Lewandowski KE, López‐Jaramillo C, Martinez‐Aran A, McIntyre RS, Porter RJ, Purdon SE, Schaffer A, Stokes P, Sumiyoshi T, Torres IJ, Van Rheenen TE, Yatham LN, Young AH, Kessing LV, Burdick KE, Vieta E. Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force. Bipolar Disord 2022; 24:354-374. [PMID: 35174594 PMCID: PMC9541874 DOI: 10.1111/bdi.13193] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND Cognitive impairments are an emerging treatment target in mood disorders, but currently there are no evidence-based pro-cognitive treatments indicated for patients in remission. With this systematic review of randomised controlled trials (RCTs), the International Society for Bipolar Disorders (ISBD) Targeting Cognition Task force provides an update of the most promising treatments and methodological recommendations. METHODS The review included RCTs of candidate pro-cognitive interventions in fully or partially remitted patients with major depressive disorder or bipolar disorder. We followed the procedures of the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) 2020 statement. Searches were conducted on PubMed/MEDLINE, PsycInfo, EMBASE and Cochrane Library from January 2015, when two prior systematic reviews were conducted, until February 2021. Two independent authors reviewed the studies with the Revised Cochrane Collaboration's Risk of Bias tool for Randomised trials. RESULTS We identified 16 RCTs (N = 859) investigating cognitive remediation (CR; k = 6; N = 311), direct current or repetitive magnetic stimulation (k = 3; N = 127), or pharmacological interventions (k = 7; N = 421). CR showed most consistent cognitive benefits, with two trials showing improvements on primary outcomes. Neuromodulatory interventions revealed no clear efficacy. Among pharmacological interventions, modafinil and lurasidone showed early positive results. Sources of bias included small samples, lack of pre-screening for objective cognitive impairment, no primary outcome and no information on allocation sequence masking. CONCLUSIONS Evidence for pro-cognitive treatments in mood disorders is emerging. Recommendations are to increase sample sizes, pre-screen for impairment in targeted domain(s), select one primary outcome, aid transfer to real-world functioning, investigate multimodal interventions and include neuroimaging.
Collapse
Affiliation(s)
- Kamilla W. Miskowiak
- Copenhagen Affective Disorder Research Centre (CADIC)Psychiatric Centre CopenhagenCopenhagen University HospitalCopenhagenDenmark,Department of PsychologyUniversity of CopenhagenCopenhagenDenmark
| | - Ida Seeberg
- Copenhagen Affective Disorder Research Centre (CADIC)Psychiatric Centre CopenhagenCopenhagen University HospitalCopenhagenDenmark,Department of PsychologyUniversity of CopenhagenCopenhagenDenmark
| | - Mette B. Jensen
- Copenhagen Affective Disorder Research Centre (CADIC)Psychiatric Centre CopenhagenCopenhagen University HospitalCopenhagenDenmark
| | - Vicent Balanzá‐Martínez
- Teaching Unit of Psychiatry and Psychological MedicineDepartment of MedicineUniversity of ValenciaCIBERSAMValenciaSpain
| | - Caterina del Mar Bonnin
- Clinical Institute of NeuroscienceHospital ClinicUniversity of BarcelonaIDIBAPSCIBERSAMBarcelonaSpain
| | | | - Andre F. Carvalho
- IMPACT Strategic Research Centre (Innovation in Mental and Physical Health and Clinical Treatment)Deakin UniversityGeelongVic.Australia
| | - Annemieke Dols
- Department of Old Age PsychiatryGGZ in GeestAmsterdam UMC, Location VUmcAmsterdam NeuroscienceAmsterdam Public Health Research InstituteAmsterdamThe Netherlands
| | - Katie Douglas
- Department of Psychological MedicineUniversity of OtagoChristchurchNew Zealand
| | - Peter Gallagher
- Translational and Clinical Research InstituteFaculty of Medical SciencesNewcastle UniversityNewcastle‐upon‐TyneUK
| | - Gregor Hasler
- Psychiatry Research UnitUniversity of FribourgFribourgSwitzerland
| | - Beny Lafer
- Bipolar Disorder Research ProgramInstitute of PsychiatryHospital das ClinicasFaculdade de MedicinaUniversidade de São PauloSão PauloSPBrazil
| | - Kathryn E. Lewandowski
- McLean HospitalSchizophrenia and Bipolar Disorder ProgramBelmontMassachusettsUSA,Department of PsychiatryHarvard Medical SchoolBostonMassachusettsUSA
| | - Carlos López‐Jaramillo
- Research Group in PsychiatryDepartment of PsychiatryUniversidad de AntioquiaMedellínColombia
| | - Anabel Martinez‐Aran
- Clinical Institute of NeuroscienceHospital ClinicUniversity of BarcelonaIDIBAPSCIBERSAMBarcelonaSpain
| | - Roger S. McIntyre
- Mood Disorders Psychopharmacology Unit, Brain and Cognition Discovery FoundationUniversity of TorontoTorontoCanada
| | - Richard J. Porter
- Department of Psychological MedicineUniversity of OtagoChristchurchNew Zealand
| | - Scot E. Purdon
- Department of PsychiatryUniversity of AlbertaEdmontonCanada
| | | | - Paul Stokes
- Department of Psychological MedicineInstitute of Psychiatry, Psychology and NeuroscienceKing’s College LondonLondonUK
| | - Tomiki Sumiyoshi
- Department of Preventive Intervention for Psychiatric DisordersNational Institute of Mental HealthNational Center of Neurology and PsychiatryTokyoJapan
| | - Ivan J. Torres
- Department of PsychiatryUniversity of British ColumbiaVancouverCanada
| | - Tamsyn E. Van Rheenen
- Melbourne Neuropsychiatry CentreDepartment of PsychiatryUniversity of MelbourneCarltonAustralia,Centre for Mental HealthFaculty of Health, Arts and DesignSwinburne UniversityAustralia
| | - Lakshmi N. Yatham
- Department of PsychiatryUniversity of British ColumbiaVancouverCanada
| | - Allan H. Young
- Department of Psychological MedicineInstitute of Psychiatry, Psychology and NeuroscienceKing’s College LondonLondonUK
| | - Lars V. Kessing
- Copenhagen Affective Disorder Research Centre (CADIC)Psychiatric Centre CopenhagenCopenhagen University HospitalCopenhagenDenmark,Department of Clinical MedicineUniversity of CopenhagenCopenhagenDenmark
| | - Katherine E. Burdick
- Department of PsychiatryHarvard Medical SchoolBostonMassachusettsUSA,Department of PsychiatryBrigham and Women’s HospitalBostonMassachusettsUSA
| | - Eduard Vieta
- Clinical Institute of NeuroscienceHospital ClinicUniversity of BarcelonaIDIBAPSCIBERSAMBarcelonaSpain
| |
Collapse
|
26
|
Karthikeyan S, Dimick MK, Fiksenbaum L, Jeong H, Birmaher B, Kennedy JL, Lanctôt K, Levitt AJ, Miller GE, Schaffer A, Young LT, Youngstrom EA, Andreazza AC, Goldstein BI. Inflammatory markers, brain-derived neurotrophic factor, and the symptomatic course of adolescent bipolar disorder: A prospective repeated-measures study. Brain Behav Immun 2022; 100:278-286. [PMID: 34896179 DOI: 10.1016/j.bbi.2021.11.020] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Revised: 11/15/2021] [Accepted: 11/29/2021] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Numerous studies have found elevated pro-inflammatory markers and reduced brain-derived neurotrophic factor (BDNF) during symptomatic episodes of bipolar disorder (BD) in adults. There is a paucity of research examining these markers in youth with BD, or longitudinally in any BD age group. METHODS 79 adolescents, ages 13-19 years, were enrolled, including 43 symptomatic adolescents with BD and 36 age-matched healthy controls (HC). Blood samples were collected from all participants at intake, and repeatedly from BD participants at pre-specified intervals over the course of two years. Serum was assayed for levels of pro-inflammatory markers (c-reactive protein [CRP], interleukin [IL]-6, tumor necrosis factor alpha [TNF-α]), BDNF and the anti-inflammatory marker, IL-10. Week-by-week severity of mood symptoms was assessed using semi-structured interviews. RESULTS Adolescents with BD provided an average of 4.6 blood samples, on average every 5.0 months. During the most severe symptomatic interval (i.e., highest sum of mood symptom scores) among BD adolescents, levels of CRP (p = 0.01) and pro- to anti-inflammatory ratios (CRP/IL-10; p < 0.001 and IL-6/IL-10; p = 0.046) were significantly greater, and IL-10 levels (p = 0.004) were significantly lower, vs. HC. There were no differences between BD and HC in IL-6, TNF-α or BDNF. Within BD participants, higher BDNF (p = 0.01) and IL-10 levels (p = 0.001) significantly predicted greater burden of mood symptoms over the subsequent epoch. Moreover, higher CRP levels (p = 0.009) at intake predicted greater time to recovery from the index symptomatic episode. CONCLUSIONS In the first repeated-measures study on this topic in adolescents with BD, we found evidence that CRP, an inexpensive and ubiquitous blood test, may be useful in predicting the prospective course of BD symptoms. Future larger studies are warranted.
Collapse
Affiliation(s)
- Sudhir Karthikeyan
- Centre for Youth Bipolar Disorder, Centre for Addiction and Mental Health, Toronto, ON, Canada; Sunnybrook Research Institute, Toronto, ON, Canada
| | - Mikaela K Dimick
- Centre for Youth Bipolar Disorder, Centre for Addiction and Mental Health, Toronto, ON, Canada; Sunnybrook Research Institute, Toronto, ON, Canada; Department of Pharmacology, University of Toronto, Toronto, ON, Canada
| | | | - Hyunjin Jeong
- Department of Pharmacology, University of Toronto, Toronto, ON, Canada; Centre for Addiction and Mental Health, Toronto, ON, Canada
| | - Boris Birmaher
- Department of Psychiatry, Western Psychiatric Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - James L Kennedy
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada
| | - Krista Lanctôt
- Department of Pharmacology, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, ON, Canada
| | - Anthony J Levitt
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, ON, Canada
| | - Gregory E Miller
- Institute for Policy Research & Department of Psychology, Northwestern University, Evanston, IL, USA
| | - Ayal Schaffer
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, ON, Canada
| | - L Trevor Young
- Department of Pharmacology, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Centre for Addiction and Mental Health, Toronto, ON, Canada
| | - Eric A Youngstrom
- Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Ana C Andreazza
- Department of Pharmacology, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Centre for Addiction and Mental Health, Toronto, ON, Canada
| | - Benjamin I Goldstein
- Centre for Youth Bipolar Disorder, Centre for Addiction and Mental Health, Toronto, ON, Canada; Sunnybrook Research Institute, Toronto, ON, Canada; Department of Pharmacology, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
| |
Collapse
|
27
|
Keramatian K, Pinto JV, Schaffer A, Sharma V, Beaulieu S, Parikh SV, Yatham LN. Clinical and demographic factors associated with delayed diagnosis of bipolar disorder: Data from Health Outcomes and Patient Evaluations in Bipolar Disorder (HOPE-BD) study. J Affect Disord 2022; 296:506-513. [PMID: 34606817 DOI: 10.1016/j.jad.2021.09.094] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Revised: 08/31/2021] [Accepted: 09/26/2021] [Indexed: 11/25/2022]
Abstract
BACKGROUND The diagnosis of Bipolar Disorder (BD) is frequently delayed. In this study, we aimed to examine the clinical and demographic factors associated with delayed diagnosis of BD, defined as the difference between the age at first mood episode (depressive, manic, or hypomanic) and the age at the correct diagnosis of BD, using data from a Canadian multicentre naturalistic study. METHODS The sample included 192 patients with Bipolar I Disorder (BD-I) and 127 with Bipolar II Disorder (BP-II) who participated in the Health Outcomes and Patient Evaluations in Bipolar Disorder (HOPE-BD) study. Sociodemographic characteristics and clinical features that had been previously associated with delayed diagnosis of BD were included in the analysis. RESULTS The median delay in diagnosis was 5.0 years in BD-I and 11.0 years in BD-II. Clinical factors such as earlier age of onset, lifetime suicide attempts and comorbid anxiety disorders were associated with a longer delay, whereas the presence of lifetime psychotic symptoms and psychiatric hospitalizations were associated with a shorter delay. Quantile regression analysis showed older age at which professional help was first sought and younger age of onset as predictors of increased delay in diagnosis of BD-I and BD-II. Depression as first episode predicted longer delay in diagnosis of BD-I but not BD-II. CONCLUSION Our findings identified the ongoing lag in identification of a BD diagnosis and the clinical markers most associated with this delay, highlighting the need for implementation of strategies for early identification and interventions in BD.
Collapse
Affiliation(s)
- Kamyar Keramatian
- Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
| | - Jairo V Pinto
- University Hospital, Federal University of Santa Catarina, Florianópolis, SC, Brazil
| | - Ayal Schaffer
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - Verinder Sharma
- Department of Psychiatry, University of Western Ontario, London, ON, Canada
| | - Serge Beaulieu
- Department of Psychiatry, McGill University, Montreal, QC, Canada
| | - Sagar V Parikh
- Department of Psychiatry, University of Michigan, Ann Arbor, MI, United States
| | - Lakshmi N Yatham
- Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
| |
Collapse
|
28
|
Yatham LN, Chakrabarty T, Bond DJ, Schaffer A, Beaulieu S, Parikh SV, McIntyre RS, Milev RV, Alda M, Vazquez G, Ravindran AV, Frey BN, Sharma V, Goldstein BI, Rej S, O'Donovan C, Tourjman V, Kozicky JM, Kauer-Sant'Anna M, Malhi G, Suppes T, Vieta E, Kapczinski F, Kanba S, Lam RW, Kennedy SH, Calabrese J, Berk M, Post R. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. Bipolar Disord 2021; 23:767-788. [PMID: 34599629 DOI: 10.1111/bdi.13135] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
OBJECTIVES The 2018 Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) guidelines provided clinicians with pragmatic treatment recommendations for bipolar disorder (BD). While these guidelines included commentary on how mixed features may direct treatment selection, specific recommendations were not provided-a critical gap which the current update aims to address. METHOD Overview of research regarding mixed presentations in BD, with treatment recommendations developed using a modified CANMAT/ISBD rating methodology. Limitations are discussed, including the dearth of high-quality data and reliance on expert opinion. RESULTS No agents met threshold for first-line treatment of DSM-5 manic or depressive episodes with mixed features. For mania + mixed features second-line treatment options include asenapine, cariprazine, divalproex, and aripiprazole. In depression + mixed features, cariprazine and lurasidone are recommended as second-line options. For DSM-IV defined mixed episodes, with a longer history of research, asenapine and aripiprazole are first-line, and olanzapine (monotherapy or combination), carbamazepine, and divalproex are second-line. Research on maintenance treatments following a DSM-5 mixed presentation is extremely limited, with third-line recommendations based on expert opinion. For maintenance treatment following a DSM-IV mixed episode, quetiapine (monotherapy or combination) is first-line, and lithium and olanzapine identified as second-line options. CONCLUSION The CANMAT and ISBD groups hope these guidelines provide valuable support for clinicians providing care to patients experiencing mixed presentations, as well as further influence investment in research to improve diagnosis and treatment of this common and complex clinical state.
Collapse
Affiliation(s)
- Lakshmi N Yatham
- Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada
| | - Trisha Chakrabarty
- Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada
| | - David J Bond
- Department of Psychiatry and Behavioral Sciences, University of Minnesota Medical School, Minneapolis, Minnesota, USA
| | - Ayal Schaffer
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Serge Beaulieu
- Department of Psychiatry, McGill University, Montreal, QC, Canada
| | - Sagar V Parikh
- Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA
| | - Roger S McIntyre
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Roumen V Milev
- Department of Psychiatry, Queens University, Kingston, Ontario, Canada
| | - Martin Alda
- Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Gustavo Vazquez
- Department of Psychiatry, Queens University, Kingston, Ontario, Canada
| | - Arun V Ravindran
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Benicio N Frey
- Department of Psychiatry and Behavioural Neurosciences, McMaster University, and St. Joseph's Healthcare, Hamilton, Ontario, Canada
| | - Verinder Sharma
- Departments of Psychiatry and Obstetrics & Gynaecology, Western University, London, Ontario, Canada
| | | | - Soham Rej
- Department of Psychiatry, McGill University, Montreal, QC, Canada
| | - Claire O'Donovan
- Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Valerie Tourjman
- Department of Psychiatry and addiction, University of Montreal, Montreal, QC, Canada
| | | | - Marcia Kauer-Sant'Anna
- Department of Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
| | - Gin Malhi
- Department of Psychiatry, University of Sydney, Sydney, Australia
| | - Trisha Suppes
- Department of Psychiatry and Behavioural Sciences, Stanford School of Medicine and VA Palo Alto Health Care System, Palo Alto, California, USA
| | - Eduard Vieta
- Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | - Flavio Kapczinski
- Department of Psychiatry and Behavioural Neurosciences, McMaster University, and St. Joseph's Healthcare, Hamilton, Ontario, Canada
| | - Shigenobu Kanba
- Department of Neuropsychiatry, Kyushu University, Fukuoka, Japan
| | - Raymond W Lam
- Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada
| | - Sidney H Kennedy
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Joseph Calabrese
- Department of Psychiatry, Western Reserve University, Cleveland, Ohio, USA
| | - Michael Berk
- IMPACT - the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Deakin University, Geelong, Australia
| | - Robert Post
- Department of Psychiatry, George Washington University, Washington, District of Columbia, USA
| |
Collapse
|
29
|
Schaffer A, Steinberg R, Sinyor M. Putting away the crystal ball: A call for clinical guidelines in mood disorders to emphasize suicide prevention interventions over assessments of risk. Bipolar Disord 2021; 23:630-631. [PMID: 33783118 DOI: 10.1111/bdi.13075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Accepted: 03/26/2021] [Indexed: 11/30/2022]
Affiliation(s)
- Ayal Schaffer
- Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - Rosalie Steinberg
- Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - Mark Sinyor
- Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
30
|
Schaffer A, Parikh SV, Toma S, Thexton N, Kcomt A, Griffiths M, Yatham LN. Expanding the target audience for management guidelines: Co-development of the patient and family guide to the CANMAT and ISBD bipolar disorder guidelines. Bipolar Disord 2021; 23:528-530. [PMID: 33934453 DOI: 10.1111/bdi.13094] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Ayal Schaffer
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - Sagar V Parikh
- Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA
| | - Simina Toma
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - Natasha Thexton
- Patient and Family Advisory Council, Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - Andrew Kcomt
- Mood Disorders Association of Ontario, Toronto, ON, Canada
| | | | - Lakshmi N Yatham
- Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
| |
Collapse
|
31
|
Côté D, Williams M, Zaheer R, Niederkrotenthaler T, Schaffer A, Sinyor M. Suicide-related Twitter Content in Response to a National Mental Health Awareness Campaign and the Association between the Campaign and Suicide Rates in Ontario. Can J Psychiatry 2021; 66:460-467. [PMID: 33563028 PMCID: PMC8107951 DOI: 10.1177/0706743720982428] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
OBJECTIVE Mental health awareness (MHA) campaigns have been shown to be successful in improving mental health literacy, decreasing stigma, and generating public discussion. However, there is a dearth of evidence regarding the effects of these campaigns on behavioral outcomes such as suicides. Therefore, the objective of this article is to characterize the association between the event and suicide in Canada's most populous province and the content of suicide-related tweets referencing a Canadian MHA campaign (Bell Let's Talk Day [BLTD]). METHODS Suicide counts during the week of BTLD were compared to a control window (2011 to 2016) to test for associations between the BLTD event and suicide. Suicide tweets geolocated to Ontario, posted in 2016 with the BLTD hashtag were coded for specific putatively harmful and protective content. RESULTS There was no associated change in suicide counts. Tweets (n = 3,763) mainly included content related to general comments about suicide death (68%) and suicide being a problem (42.8%) with little putatively helpful content such as stories of resilience (0.6%) and messages of hope (2.2%). CONCLUSIONS In Ontario, this national mental health media campaign was associated with a high volume of suicide-related tweets but not necessarily including content expected to diminish suicide rates. Campaigns like BLTD should strongly consider greater attention to suicide-related messaging that promotes help-seeking and resilience. This may help to further decrease stigmatization, and potentially, reduce suicide rates.
Collapse
Affiliation(s)
- David Côté
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,University of Toronto, Ontario, Canada
| | - Marissa Williams
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Athabasca University, Alberta, Canada
| | - Rabia Zaheer
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,University of Waterloo, Ontario, Canada
| | - Thomas Niederkrotenthaler
- Center for Public Health, Department of Social and Preventive Medicine, Medical University of Vienna, Unit Suicide Research & Mental Health Promotion, Vienna, Austria
| | - Ayal Schaffer
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, University of Toronto, Ontario Canada
| | - Mark Sinyor
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, University of Toronto, Ontario Canada
| |
Collapse
|
32
|
Sinyor M, Williams M, Zaheer R, Loureiro R, Pirkis J, Heisel MJ, Schaffer A, Redelmeier DA, Cheung AH, Niederkrotenthaler T. The association between Twitter content and suicide. Aust N Z J Psychiatry 2021; 55:268-276. [PMID: 33153274 DOI: 10.1177/0004867420969805] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
OBJECTIVE A growing body of research has established that specific elements of suicide-related news reporting can be associated with increased or decreased subsequent suicide rates. This has not been systematically investigated for social media. The aim of this study was to identify associations between specific social media content and suicide deaths. METHODS Suicide-related tweets (n = 787) geolocated to Toronto, Canada and originating from the highest level influencers over a 1-year period (July 2015 to June 2016) were coded for general, putatively harmful and putatively protective content. Multivariable logistic regression was used to examine whether tweet characteristics were associated with increases or decreases in suicide deaths in Toronto in the 7 days after posting, compared with a 7-day control window. RESULTS Elements independently associated with increased subsequent suicide counts were tweets about the suicide of a local newspaper reporter (OR = 5.27, 95% CI = [1.27, 21.99]), 'other' social causes of suicide (e.g. cultural, relational, legal problems; OR = 2.39, 95% CI = [1.17, 4.86]), advocacy efforts (OR = 2.34, 95% CI = [1.48, 3.70]) and suicide death (OR = 1.52, 95% CI = [1.07, 2.15]). Elements most strongly independently associated with decreased subsequent suicides were tweets about murder suicides (OR = 0.02, 95% CI = [0.002, 0.17]) and suicide in first responders (OR = 0.17, 95% CI = [0.05, 0.52]). CONCLUSIONS These findings largely comport with the theory of suicide contagion and associations observed with traditional news media. They specifically suggest that tweets describing suicide deaths and/or sensationalized news stories may be harmful while those that present suicide as undesirable, tragic and/or preventable may be helpful. These results suggest that social media is both an important exposure and potential avenue for intervention.
Collapse
Affiliation(s)
- Mark Sinyor
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.,Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - Marissa Williams
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.,Graduate Centre for Applied Psychology, Athabasca University, Athabasca, AB, Canada
| | - Rabia Zaheer
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.,Faculty of Applied Health Sciences, University of Waterloo, Waterloo, ON, Canada
| | - Raisa Loureiro
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - Jane Pirkis
- Centre for Mental Health, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia
| | - Marnin J Heisel
- Departments of Psychiatry and of Epidemiology and Biostatistics, University of Western Ontario, London, ON, Canada
| | - Ayal Schaffer
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.,Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - Donald A Redelmeier
- Department of Medicine, University of Toronto, Toronto, ON, Canada.,Sunnybrook Research Institute, Toronto, ON, Canada.,Division of General Internal Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.,Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
| | - Amy H Cheung
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.,Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - Thomas Niederkrotenthaler
- Unit Suicide Research & Mental Health Promotion, Department of Social and Preventive Medicine, Center for Public Health, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
33
|
Fotso Soh J, Beaulieu S, Trepiccione F, Linnaranta O, Torres-Platas G, Platt RW, Renaud S, Su CL, Mucsi I, D'Apolito L, Mulsant BH, Levinson A, Saury S, Müller D, Schaffer A, Dols A, Low N, Cervantes P, Christensen BM, Herrmann N, Rajji T, Rej S. A double-blind, randomized, placebo-controlled pilot trial of atorvastatin for nephrogenic diabetes insipidus in lithium users. Bipolar Disord 2021; 23:66-75. [PMID: 32621644 DOI: 10.1111/bdi.12973] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/22/2019] [Revised: 06/17/2020] [Accepted: 06/24/2020] [Indexed: 12/28/2022]
Abstract
OBJECTIVE Lithium remains an important treatment for mood disorders but is associated with kidney disease. Nephrogenic diabetes insipidus (NDI) is associated with up to 3-fold risk of incident chronic kidney disease among lithium users. There are limited randomized controlled trials (RCT) for treatments of lithium-induced NDI, and existing therapies can be poorly tolerated. Therefore, novel treatments are needed for lithium-induced NDI. METHOD We conducted a 12-week double-blind pilot RCT to assess the feasibility and efficacy of 20 mg/d atorvastatin vs placebo in the treatment of NDI in chronic lithium users. Patients, recruited between September 2017 and October 2018, were aged 18 to 85, currently on a stable dose of lithium, and determined to have NDI. RESULTS Urinary osmolality (UOsm) at 12 weeks adjusted for baseline was not statistically different between groups (+39.6 mOsm/kg [95% CI, -35.3, 114.5] in atorvastatin compared to placebo groups). Secondary outcomes of fluid intake and aquaporin-2 excretions at 12 weeks adjusted for baseline were -0.13 L [95% CI, -0.54, 0.28] and 98.68 [95% CI, -190.34, 387.70], respectively. A moderate effect size was observed for improvements in baseline UOsm by ≥100 mOsm/kg at 12 weeks in patients who received atorvastatin compared to placebo (38.45% (10/26) vs 22.58% (7/31); Cohen's d = 0.66). CONCLUSION Among lithium users with NDI, atorvastatin 20 mg/d did not significantly improve urinary osmolality compared to placebo over a 12-week period. Larger confirmatory trials with longer follow-up periods may help to further assess the effects of statins on NDI, especially within patients with more severe NDI.
Collapse
Affiliation(s)
- Jocelyn Fotso Soh
- Geri-PARTy Research Group, Jewish General Hospital, Montreal, QC, Canada.,Douglas Mental Health University Institute, Montreal, QC, Canada
| | - Serge Beaulieu
- Douglas Mental Health University Institute, Montreal, QC, Canada
| | | | - Outi Linnaranta
- Douglas Mental Health University Institute, Montreal, QC, Canada
| | | | - Robert W Platt
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University Health Centre, Montreal, QC, Canada
| | - Suzane Renaud
- Douglas Mental Health University Institute, Montreal, QC, Canada
| | - Chien-Lin Su
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University Health Centre, Montreal, QC, Canada
| | - Istvan Mucsi
- Division of Nephrology, University Health Network, University of Toronto (UofT), Toronto, ON, Canada
| | - Luciano D'Apolito
- Biogem S.c.a.r.l., Istituto di Ricerche Genetiche "Gaetano Salvatore", Ariano Irpino, Italy
| | - Benoit H Mulsant
- Department of Psychiatry, Centre for Addiction and Mental Health & Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - Andrea Levinson
- Department of Psychiatry, Centre for Addiction and Mental Health & Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - Sybille Saury
- Douglas Mental Health University Institute, Montreal, QC, Canada
| | - Daniel Müller
- Department of Psychiatry, Centre for Addiction and Mental Health & Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - Ayal Schaffer
- Department of Psychiatry, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada
| | - Annemiek Dols
- Amsterdam UMC, Department of Psychiatry, GGZinGeest, Neuroscience, Amsterdam, The Netherlands
| | - Nancy Low
- Department of Psychiatry, McGill University Health Centre, Montreal, QC, Canada
| | - Pablo Cervantes
- Department of Psychiatry, McGill University Health Centre, Montreal, QC, Canada
| | | | - Nathan Herrmann
- Department of Psychiatry, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada
| | - Tarek Rajji
- Department of Psychiatry, Centre for Addiction and Mental Health & Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - Soham Rej
- Geri-PARTy Research Group, Jewish General Hospital, Montreal, QC, Canada.,Douglas Mental Health University Institute, Montreal, QC, Canada
| |
Collapse
|
34
|
Cheung CP, Thiyagarajah MT, Abraha HY, Liu CS, Lanctôt KL, Kiss AJ, Saleem M, Juda A, Levitt AJ, Schaffer A, Cheung AH, Sinyor M. The association between placebo arm inclusion and adverse event rates in antidepressant randomized controlled trials: An examination of the Nocebo Effect. J Affect Disord 2021; 280:140-147. [PMID: 33212405 DOI: 10.1016/j.jad.2020.11.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/02/2019] [Revised: 07/27/2020] [Accepted: 11/01/2020] [Indexed: 12/29/2022]
Abstract
BACKGROUND Antidepressant efficacy is influenced by patient expectations and, in randomized controlled trials (RCTs), the probability of receiving a placebo. It is unclear whether tolerability demonstrates a similar pattern. This study aimed to determine whether study design influences adverse event (AE) rates in antidepressant trials for subjects receiving active treatment or placebo. METHODS RCTs comparing one antidepressant to another antidepressant, placebo, or both in major depressive disorder (MDD) (1996-2018) were retrieved from Medline and PsycINFO. Clinicaltrials.gov was searched for unpublished trials. Of 1,997 studies screened, 77 trials were included. Studies were classified as drug-drug, drug-drug-placebo, or drug-placebo based on design and overall number of subjects experiencing any AE was recorded. Subgroup meta-analysis of proportions and meta-regression techniques were used to compare AE rates across study designs in patients receiving active antidepressant treatment and placebo. RESULTS Among the actively treated, AE rates were lower in drug-drug trials (58.5%) compared to drug-drug-placebo (75.7%) and drug-placebo (76.4%) (the model reported coefficients for percent differences between AE rates of different study designs were B=17.0, p<0.001 and B=17.8, p<0.001, respectively). AE rates in patients receiving placebo were not different between study designs. LIMITATIONS The present study is limited by the diverse range of study populations, variability in reporting of AEs, and specific antidepressants employed in the included trials. CONCLUSIONS The inclusion of a placebo arm in the study design was unexpectedly associated with higher rates of AEs among patients receiving active medication in antidepressant trials. This observation has important implications for interpretation of trial tolerability findings.
Collapse
Affiliation(s)
- Christian P Cheung
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Mathura T Thiyagarajah
- Neuropsychopharmacology Research Program, Department of Psychiatry, Sunnybrook Health Sciences Centre; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada
| | - Haben Y Abraha
- Neuropsychopharmacology Research Program, Department of Psychiatry, Sunnybrook Health Sciences Centre; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada
| | - Celina S Liu
- Neuropsychopharmacology Research Program, Department of Psychiatry, Sunnybrook Health Sciences Centre; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada
| | - Krista L Lanctôt
- Neuropsychopharmacology Research Program, Department of Psychiatry, Sunnybrook Health Sciences Centre; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada
| | - Alex J Kiss
- Department of Research Design and Biostatistics, Sunnybrook Research Institute, Toronto, Canada
| | - Mahwesh Saleem
- Neuropsychopharmacology Research Program, Department of Psychiatry, Sunnybrook Health Sciences Centre; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada
| | - Ari Juda
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Anthony J Levitt
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Ayal Schaffer
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Amy H Cheung
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Mark Sinyor
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada.
| |
Collapse
|
35
|
Swainson J, McGirr A, Blier P, Brietzke E, Richard-Devantoy S, Ravindran N, Blier J, Beaulieu S, Frey BN, Kennedy SH, McIntyre RS, Milev RV, Parikh SV, Schaffer A, Taylor VH, Tourjman V, van Ameringen M, Yatham LN, Ravindran AV, Lam RW. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur. Can J Psychiatry 2021; 66:113-125. [PMID: 33174760 PMCID: PMC7918868 DOI: 10.1177/0706743720970860] [Citation(s) in RCA: 48] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
OBJECTIVE Patients with major depressive disorder often have limited response to first-line and second-line medications; hence, novel pharmacological treatments are needed for treatment-resistant depression (TRD). Ketamine, an N-methyl-d-aspartate (NMDA) receptor antagonist, has demonstrated rapid antidepressant effects in patients with TRD. The Canadian Network for Mood and Anxiety Treatments (CANMAT) convened a task force to review the evidence for efficacy and safety of racemic ketamine and to provide recommendations for its use in clinical practice. METHODS A systematic review was conducted with computerized search of electronic databases up to January 31, 2020 using combinations of search terms, inspection of bibliographies, and review of other ketamine guidelines and consensus statements. The level of evidence and lines of treatment were assigned according to CANMAT criteria. Recommendations were given in question-answer format. RESULTS Intravenous (IV) racemic ketamine given as a single infusion has Level 1 evidence for efficacy in adults with TRD. The evidence for multiple infusions, given as an acute series or as ongoing maintenance treatment, is limited to Level 3. Adverse events associated with ketamine infusions include behavioral (e.g., dissociative symptoms) and physiological (e.g., hypertension) events. There is only Level 3 or 4 evidence for non-IV formulations of racemic ketamine. Consensus recommendations are given for clinical administration of IV ketamine including patient selection, facility and personnel issues, monitoring, and maintaining response. CONCLUSIONS Single-dose IV racemic ketamine is a third-line recommendation for adults with TRD. The need for repeated and maintenance ketamine infusions should be carefully assessed on a case-by-case basis with consideration of potential risks and benefits. Because of limited evidence for efficacy and risk for misuse and diversion, the use of oral and other formulations of racemic ketamine should be limited to specialists with ketamine-prescribing expertise and affiliations with tertiary or specialized centers.
Collapse
Affiliation(s)
- Jennifer Swainson
- Department of Psychiatry, 12357University of Alberta, Edmonton, Alberta, Canada
| | - Alexander McGirr
- Department of Psychiatry, 70401University of Calgary, Alberta, Canada
| | - Pierre Blier
- Department of Psychiatry, 12365University of Ottawa, Ontario, Canada
| | - Elisa Brietzke
- Department of Psychiatry, 104820Queen's University, Kingston, Ontario, Canada
| | | | - Nisha Ravindran
- Department of Psychiatry, 12366University of Toronto, Ontario, Canada
| | - Jean Blier
- Department of Anesthesiology and Pain Medicine, 12365University of Ottawa, Ontario, Canada
| | - Serge Beaulieu
- Department of Psychiatry, 12367McGill University, Montreal, Quebec, Canada
| | - Benicio N Frey
- Department of Psychiatry and Behavioural Neurosciences, 62703McMaster University, Hamilton, Ontario, Canada
| | - Sidney H Kennedy
- Department of Psychiatry, 12366University of Toronto, Ontario, Canada
| | - Roger S McIntyre
- Department of Psychiatry, 12366University of Toronto, Ontario, Canada
| | - Roumen V Milev
- Department of Psychiatry, 104820Queen's University, Kingston, Ontario, Canada
| | - Sagar V Parikh
- Department of Psychiatry, 12266University of Michigan, Ann Arbor, Michigan, USA
| | - Ayal Schaffer
- Department of Psychiatry, 12366University of Toronto, Ontario, Canada
| | - Valerie H Taylor
- Department of Psychiatry, 70401University of Calgary, Alberta, Canada
| | - Valérie Tourjman
- Department of Psychiatry, 12368Université de Montréal, Québec, Canada
| | - Michael van Ameringen
- Department of Psychiatry and Behavioural Neurosciences, 62703McMaster University, Hamilton, Ontario, Canada
| | - Lakshmi N Yatham
- Department of Psychiatry, 8166University of British Columbia, Vancouver, British Columbia, Canada
| | - Arun V Ravindran
- Department of Psychiatry, 12366University of Toronto, Ontario, Canada
| | - Raymond W Lam
- Department of Psychiatry, 8166University of British Columbia, Vancouver, British Columbia, Canada
| |
Collapse
|
36
|
Do A, Keramatian K, Schaffer A, Yatham L. Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials. Front Psychiatry 2021; 12:769897. [PMID: 34970166 PMCID: PMC8712443 DOI: 10.3389/fpsyt.2021.769897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/02/2021] [Accepted: 11/19/2021] [Indexed: 12/01/2022] Open
Abstract
Bipolar disorder (BD) is chronic psychiatric disorder associated with significant impairment in psychosocial functioning and quality of life. Although current pharmacological treatments for BD have improved its clinical management, many patients do not achieve remission, particularly those suffering from bipolar depression. In addition, available treatments are associated with a myriad of potential adverse effects, which highlights the need for novel therapeutic agents that can be effective for both phases of the illness with a reduced side effect burden. Cariprazine is a novel antipsychotic that is a dopamine D2/D3 partial agonist with a preference for D3 receptors. In this review, we examine the pharmacological properties, clinical efficacy and tolerability profile of cariprazine in patients with BD, taking into account the latest clinical trials data. We also review post hoc analyses addressing clinically relevant subgroups and symptom domains in BD. Current evidence suggests efficacy for cariprazine 3-12 mg/day in the treatment of acute manic and mixed episodes; for bipolar depression, the efficacy of cariprazine appears to be dose-related, with doses of 1.5-3 mg/day beneficial as monotherapy. Cariprazine is overall well-tolerated by patients in both manic and depressive episodes. Its most common side effects relative to placebo include akathisia, extrapyramidal symptoms and nausea. There are no metabolic concerns reported with cariprazine use. In summary, the latest evidence suggests that cariprazine is an effective and safe treatment option for BD.
Collapse
Affiliation(s)
- André Do
- Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
| | - Kamyar Keramatian
- Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
| | - Ayal Schaffer
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - Lakshmi Yatham
- Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
| |
Collapse
|
37
|
Sinyor M, Kiss A, Williams M, Zaheer R, Pirkis J, Heisel MJ, Schaffer A, Redelmeier DA, Cheung AH, Niederkrotenthaler T. Changes in Suicide Reporting Quality and Deaths in Ontario Following Publication of National Media Guidelines. Crisis 2020; 42:378-385. [PMID: 33241743 DOI: 10.1027/0227-5910/a000737] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Background: Media guidelines can influence suicide-related reporting quality and may impact suicide rates. Aim: Our study aimed to investigate the quality of suicide-related reporting after the release of the 2009 Canadian Psychiatric Association (CPA) guidelines and their impact on suicides. Method: A random sample of suicide-related articles (n = 988) were retrieved from 12 major Canadian print/online publications (2002-2015). Articles were coded for quality of content before and after guidelines release. Suicide mortality data were obtained from Ontario coroner records. Time series analyses were used to identify associations between guideline publication and subsequent suicides. Results: The CPA guidelines were associated with improvements in reporting quality with 10 putatively harmful elements being less frequent after their publication. These included less frequent front-page articles, monocausal (simplistic) explanations for suicide, and depictions of suicide methods. Two putatively protective factors, alternatives to suicide and messages of hope, were twice and four times as common, respectively, after the guidelines. The guidelines were not associated with a change in suicide counts. Limitations: This study could not prove exposure to suicide reporting. Conclusion: Publication of Canadian media guidelines was associated with significant, moderate-sized improvements in reporting quality but not with decreased suicides. The latter finding may reflect only modest dissemination and implementation of the guidelines.
Collapse
Affiliation(s)
- Mark Sinyor
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.,Department of Psychiatry, University of Toronto, ON, Canada
| | - Alex Kiss
- Institute for Clinical Evaluative Sciences, Toronto, ON, Canada.,Department of Health Policy, Management and Evaluation, University of Toronto, ON, Canada
| | - Marissa Williams
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.,Graduate Centre for Applied Psychology, Athabasca University, AB, Canada
| | - Rabia Zaheer
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - Jane Pirkis
- Centre for Mental Health, University of Melbourne, VIC, Australia
| | - Marnin J Heisel
- Department of Psychiatry, The University of Western Ontario, London, ON, Canada
| | - Ayal Schaffer
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.,Department of Psychiatry, University of Toronto, ON, Canada
| | - Donald A Redelmeier
- Institute for Clinical Evaluative Sciences, Toronto, ON, Canada.,Department of Medicine, University of Toronto, ON, Canada.,Division of General Internal Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - Amy H Cheung
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.,Department of Psychiatry, University of Toronto, ON, Canada
| | - Thomas Niederkrotenthaler
- Center for Public Health, Department of Social and Preventive Medicine, Unit Suicide Research & Mental Health Promotion, Medical University of Vienna, Austria
| |
Collapse
|
38
|
Hatcher S, Heisel M, Ayonrinde O, Campbell JK, Colman I, Corsi DJ, Edgar NE, Gillett L, Kennedy SH, Hunt SL, Links P, MacLean S, Mehta V, Mushquash C, Raimundo A, Rizvi SJ, Saskin R, Schaffer A, Sidahmed A, Sinyor M, Soares C, Taljaard M, Testa V, Thavorn K, Thiruganasambandamoorthy V, Vaillancourt C. The BEACON study: protocol for a cohort study as part of an evaluation of the effectiveness of smartphone-assisted problem-solving therapy in men who present with intentional self-harm to emergency departments in Ontario. Trials 2020; 21:925. [PMID: 33187542 PMCID: PMC7663866 DOI: 10.1186/s13063-020-04424-w] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2020] [Accepted: 05/16/2020] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND Patients who present to emergency departments after intentional self-harm are at an increased risk of dying by suicide. This applies particularly to men, who represent nearly two-thirds of those who die by suicide in Ontario. One way of potentially addressing this gap is to offer a course of blended problem-solving therapy, comprised of a brief course of evidence-based psychotherapy for individuals at risk for suicide, facilitated by the use of a patient-facing smartphone application and a clinician-facing "dashboard." This approach has the potential to combine the benefits of face-to-face therapy and technology to create a novel intervention. METHODS This is a cohort study nested within a larger pragmatic multicentre pre- and post-design cluster randomised trial. Suicidal ideation assessed by the Beck Scale for Suicide Ideation is the primary outcome variable. Secondary outcome measures include depression (Patient Health Questionnaire-9), anxiety (Generalized Anxiety Disorder 7-item scale), post-traumatic stress disorder (Primary Care PTSD Screen), health-related quality of life (EuroQol 5-dimension 5-level questionnaire), meaning in life (Experienced Meaning in Life Scale), perceived social supports (Multidimensional Scale of Perceived Social Support), alcohol use (Alcohol Use Disorders Identification Test), drug use (Drug Abuse Screening Test Short Form 10), problem-solving skills (Social Problem-Solving Inventory-Revised Short Form), and self-reported healthcare costs, as well as health service use measured using Ontario administrative health data. A process evaluation will also be conducted following study completion. DISCUSSION The cohort study will test whether better adherence to the intervention results in better outcomes. The value of the cohort study design is that we can examine in more detail certain subgroups or other variables that are not available in the larger cluster randomised trial. This trial will aim to improve standards by informing best practice in management of men who self-harm and present to hospitals in Ontario. TRIAL REGISTRATION ClinicalTrials.gov , NCT03473535 . Registered on March 22, 2018.
Collapse
Affiliation(s)
- Simon Hatcher
- Ottawa Hospital Research Institute, Ottawa, Canada.
- University of Ottawa, Ottawa, Canada.
| | - Marnin Heisel
- Lawson Health Research Institute, London, Canada
- Western University, London, Canada
| | - Oyedeji Ayonrinde
- Queen's University, Kingston, Canada
- Kingston Health Sciences Centre, Kingston, Canada
| | | | | | - Daniel J Corsi
- Ottawa Hospital Research Institute, Ottawa, Canada
- University of Ottawa, Ottawa, Canada
| | | | - Lindsay Gillett
- Sioux Lookout Meno Ya Win Health Centre, Sioux Lookout, Canada
| | - Sidney H Kennedy
- St. Michael's Hospital, Toronto, Canada
- University of Toronto, Toronto, Canada
| | | | | | - Sarah MacLean
- Ottawa Hospital Research Institute, Ottawa, Canada
- Carleton University, Ottawa, Canada
| | | | | | - Alicia Raimundo
- Ottawa Hospital Research Institute, Ottawa, Canada
- University of Ottawa, Ottawa, Canada
| | - Sakina J Rizvi
- St. Michael's Hospital, Toronto, Canada
- University of Toronto, Toronto, Canada
| | - Refik Saskin
- Institute for Clinical Evaluative Sciences, Toronto, Canada
| | - Ayal Schaffer
- University of Toronto, Toronto, Canada
- Sunnybrook Research Institute, Toronto, Canada
| | | | - Mark Sinyor
- University of Toronto, Toronto, Canada
- Sunnybrook Research Institute, Toronto, Canada
| | - Claudio Soares
- Queen's University, Kingston, Canada
- Kingston Health Sciences Centre, Kingston, Canada
| | - Monica Taljaard
- Ottawa Hospital Research Institute, Ottawa, Canada
- University of Ottawa, Ottawa, Canada
| | - Valerie Testa
- Ottawa Hospital Research Institute, Ottawa, Canada
- University of Ottawa, Ottawa, Canada
| | - Kednapa Thavorn
- Ottawa Hospital Research Institute, Ottawa, Canada
- University of Ottawa, Ottawa, Canada
| | | | | |
Collapse
|
39
|
Conforti P, Zaheer R, Goldstein BI, Levitt AJ, Schaffer A, Fefergrad M, Cheung AH, Sinyor M. The Feasibility of a Harry Potter-based Cognitive Behavioural Therapy Skills Curriculum on Suicidality and Well-being in Middle Schoolers. Can J Psychiatry 2020; 65:811-813. [PMID: 32701402 PMCID: PMC7564693 DOI: 10.1177/0706743720944046] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Paula Conforti
- College of Psychologists of Ontario, Toronto, Ontario, Canada.,Institute of Medical Science, Faculty of Medicine, 7938University of Toronto, Ontario, Canada
| | - Rabia Zaheer
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,University of Waterloo, Ontario, Canada
| | - Benjamin I Goldstein
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, 7938University of Toronto, Ontario, Canada
| | - Anthony J Levitt
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, 7938University of Toronto, Ontario, Canada
| | - Ayal Schaffer
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, 7938University of Toronto, Ontario, Canada
| | - Mark Fefergrad
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, 7938University of Toronto, Ontario, Canada
| | - Amy H Cheung
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, 7938University of Toronto, Ontario, Canada
| | - Mark Sinyor
- Department of Psychiatry, 71545Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, 7938University of Toronto, Ontario, Canada
| |
Collapse
|
40
|
Barakat A, Siers D, Schaffer A, John R, Kaizer A, Perry T, Lanigan M. Variability in adherence to goal-directed transfusion protocols and inter-physician variability: an odd phenomenon. J Cardiothorac Vasc Anesth 2020. [DOI: 10.1053/j.jvca.2020.09.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
41
|
Hayden J, Webber E, Pfenning-Wendt R, Schaffer A, Harder K, Perry T. Clinician-driven model creates opportunity for perioperative patient education AIDS. J Cardiothorac Vasc Anesth 2020. [DOI: 10.1053/j.jvca.2020.09.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
42
|
Sinyor M, Schaffer A. The Lack of Adequate Scientific Evidence Regarding Physician-assisted Death for People with Psychiatric Disorders Is a Danger to Patients. Can J Psychiatry 2020; 65:607-609. [PMID: 32452224 PMCID: PMC7485040 DOI: 10.1177/0706743720928658] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Mark Sinyor
- Department of Psychiatry, 494622Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, University of Toronto, Ontario, Canada
| | - Ayal Schaffer
- Department of Psychiatry, 494622Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, University of Toronto, Ontario, Canada
| |
Collapse
|
43
|
Dimick MK, Omrin D, MacIntosh BJ, Mitchell RHB, Riegert D, Levitt A, Schaffer A, Belo S, Iazzetta J, Detzler G, Choi M, Choi S, Orser BA, Goldstein BI. Nitrous oxide as a putative novel dual-mechanism treatment for bipolar depression: Proof-of-concept study design and methodology. Contemp Clin Trials Commun 2020; 19:100600. [PMID: 32637725 PMCID: PMC7327241 DOI: 10.1016/j.conctc.2020.100600] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2020] [Revised: 06/10/2020] [Accepted: 06/21/2020] [Indexed: 12/23/2022] Open
Abstract
Introduction Depressive symptoms predominate in the course of bipolar disorder (BD) and there is an urgent need to evaluate novel application of repurposed compounds that act on pre-specified treatment targets. Several lines of reasoning suggest that nitrous oxide (N2O) is an ideal medication to study as a potential treatment and as a strategy to identify the underlying pathophysiology of bipolar depression. N2O is a potent cerebral vasodilator and there is compelling evidence of reduced frontal cerebral blood flow (CBF; i.e. hypoperfusion) in depression. Therefore, N2O may increase CBF and thereby improve symptoms of depression. The goal of this randomized, double-blind trial is to study the effect of a single administration of N2O versus the active comparator midazolam on mood and CBF in adults with treatment-resistant bipolar depression. Methods Participants with BD-I/-II currently experiencing a major depressive episode will be randomized to one of two conditions (n = 20/group): 1) inhaled N2O plus intravenous saline, or 2) inhaled room air plus intravenous midazolam. Montgomery-Asberg Depression Rating Scale scores will serve as the primary endpoint. CBF will be measured via arterial spin labelling magnetic resonance imaging. Conclusions N2O is a potential novel treatment for bipolar depression, as it causes cerebral vasodilation. This proof-of-concept study will provide valuable information regarding the acute impact of N2O on mood and on CBF. If N2O proves to be efficacious in future larger-scale trials, its ubiquity, safety, low cost, and ease of use suggest that it has great potential to become a game-changing acute treatment for bipolar depression.
Collapse
Affiliation(s)
- Mikaela K Dimick
- Pharmacology and Toxicology Department, University of Toronto, Toronto, Ontario, Canada.,Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Danielle Omrin
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Bradley J MacIntosh
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
| | - Rachel H B Mitchell
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Daniel Riegert
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Anesthesia, University of Toronto, Toronto, Ontario, Canada
| | - Anthony Levitt
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Ayal Schaffer
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Susan Belo
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Anesthesia, University of Toronto, Toronto, Ontario, Canada
| | - John Iazzetta
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Pharmacy Department, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | | | - Mabel Choi
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Anesthesia, University of Toronto, Toronto, Ontario, Canada
| | - Stephen Choi
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Anesthesia, University of Toronto, Toronto, Ontario, Canada
| | - Beverley A Orser
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Anesthesia, University of Toronto, Toronto, Ontario, Canada
| | - Benjamin I Goldstein
- Pharmacology and Toxicology Department, University of Toronto, Toronto, Ontario, Canada.,Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
44
|
Abstract
Suicide is among the most important causes of mortality in medicine as it is the most common cause of death due to illness from the teenage years into middle age. Yet our approach to mental health research aimed at suicide prevention has often diverged from accepted practices in other areas of medicine. This includes the exclusion of those at highest risk of suicide from clinical trials and the recent emphasis on prediction. In this Viewpoint, we propose that comparing our approach to that of other medical specialties would help us to avoid strategic errors and discuss the implications for the field of suicide prevention.
Collapse
Affiliation(s)
- Mark Sinyor
- Mood and Anxiety Disorders Program, Sunnybrook Health Sciences Centre, Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - Ayal Schaffer
- Mood and Anxiety Disorders Program, Sunnybrook Health Sciences Centre, Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
45
|
Sinyor M, Williams M, Zaheer R, Loureiro R, Pirkis J, Heisel MJ, Schaffer A, Cheung AH, Redelmeier DA, Niederkrotenthaler T. The Relationship Between Suicide-Related Twitter Events and Suicides in Ontario From 2015 to 2016. Crisis 2020; 42:40-47. [PMID: 32366171 DOI: 10.1027/0227-5910/a000684] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Background: Many studies have demonstrated suicide contagion through mainstream journalism; however, few have explored suicide-related social media events and their potential relationship to suicide deaths. Aims: To determine whether Twitter events were associated with changes in subsequent suicides. Methods: Suicide-related Twitter events that garnered at least 100 tweets originating in Ontario, Canada (July 1, 2015 to June 30, 2016) were identified and characterized as putatively "harmful" or "innocuous" based on recommendations for responsible media reporting. The number of suicides in Ontario during the peak of each Twitter event and the subsequent 6 days ("exposure window") was compared with suicides occurring during a pre-event period of the same length ("control window"). Results: There were 17 suicide-related Twitter events during the period of study (12 putatively harmful and five putatively innocuous). The number of tweets per event ranged from 121 for "physician-assisted suicide law in Quebec" to 6,202 for the "Attawapiskat suicide crisis." No significant relationship was detected between Twitter events and actual suicides. Notably, a comprehensive examination of the details of Twitter events showed that even the putatively harmful events lacked many of the characteristics commonly associated with contagion. Limitations: This was an uncontrolled experiment in only one epoch and a single Canadian province. Discussion: This study found no evidence of suicide contagion associated with Twitter events. This finding must be interpreted with caution given the relatively innocuous content of suicide-related Tweets in Ontario during 2015-2016.
Collapse
Affiliation(s)
- Mark Sinyor
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.,Department of Psychiatry, University of Toronto, ON, Canada
| | - Marissa Williams
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.,Graduate Centre for Applied Psychology, Athabasca University, AB, Canada
| | - Rabia Zaheer
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - Raisa Loureiro
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - Jane Pirkis
- Centre for Mental Health, Melbourne School of Population and Global Health, University of Melbourne, VIC, Australia
| | - Marnin J Heisel
- Department of Psychiatry, The University of Western Ontario, London, ON, Canada
| | - Ayal Schaffer
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.,Department of Psychiatry, University of Toronto, ON, Canada
| | - Amy H Cheung
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.,Department of Psychiatry, University of Toronto, ON, Canada
| | - Donald A Redelmeier
- Department of Medicine, University of Toronto, ON, Canada.,Division of General Internal Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.,Institute for Clinical Evaluative Sciences, Toronto, ON, Canada.,Evaluative Clinical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada
| | - Thomas Niederkrotenthaler
- Centre for Public Health, Department of Social and Preventive Medicine, Unit Suicide Research & Mental Health Promotion, Medical University of Vienna, Austria
| |
Collapse
|
46
|
Sinyor M, Hawes D, Rector NA, Cheung AH, Williams M, Cheung C, Goldstein BI, Fefergrad M, Levitt AJ, Schaffer A. Preliminary Investigation of a Novel Cognitive Behavioural Therapy Curriculum on the Wellbeing of Middle Schoolers. J Can Acad Child Adolesc Psychiatry 2020; 29:66-75. [PMID: 32405309 PMCID: PMC7213921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 06/13/2019] [Accepted: 10/19/2019] [Indexed: 06/11/2023]
Abstract
OBJECTIVES A number of school-based interventions for preventing and attenuating symptoms of anxiety and depression in youth have been developed worldwide but evidence of their effectiveness is mixed. None of these curricula stem from existing children's literature, however, the Harry Potter (HP) series has been identified as potentially imparting Cognitive Behavioural Therapy concepts. METHODS This study aimed to broadly capture, at an interim stage, the feasibility of a pilot HP curriculum aimed at imparting CBT skills to middle-schoolers in order to inform full development of the curriculum. The study design further included a non-randomized, Group (HP; Control) by Time (Baseline, Post-Intervention, Follow-up) mixed factorial approach retrospectively examining change in scores on a "Well-Being and Resiliency Survey" (WBRS) which assessed multiple symptomatic and social domains. RESULTS In total, 232 grade seven and eight students participated in the curriculum over two years with no dropouts. Compared to 362 controls, there were no significant differences in WBRS scores between groups at post or one-year follow-up. CONCLUSIONS This pilot study demonstrated the feasibility of rapid and broad implementation of the intervention. Preliminary analyses showed no indication of effectiveness which may be the product of the intervention being in an interim stage during the study period and/or the retrospective design and limitations in data quality. Specifically, these results suggest that the WBRS may be a suboptimal instrument for measuring the effectiveness of this intervention. A prospective trial of the complete, revised curriculum with validated measures is required to provide an adequately assessment of its impact.
Collapse
Affiliation(s)
- Mark Sinyor
- Associate Professor, Department of Psychiatry, University of Toronto. Psychiatrist, Sunnybrook Health Sciences Centre, Toronto, Ontario
| | - Donaleen Hawes
- Psychologist and Superintendent of Education, Catholic District School Board of Eastern Ontario, Kemptville, Ontario
| | - Neil A Rector
- Professor, Departments of Psychiatry and Psychological Clinical Science, University of Toronto, Toronto, Ontario
| | - Amy H Cheung
- Associate Professor, Department of Psychiatry, University of Toronto; Psychiatrist, Sunnybrook Health Sciences Centre, Toronto, Ontario
| | - Marissa Williams
- Research Coordinator, Sunnybrook Health Sciences Centre, Toronto, Canada; Master of Counselling Psychology Student, Athabasca University, Athabasca, Alberta
| | - Christian Cheung
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario
| | - Benjamin I Goldstein
- Professor, Department of Psychiatry, University of Toronto; Psychiatrist, Sunnybrook Health Sciences Centre, Toronto, Ontario
| | - Mark Fefergrad
- Assistant Professor and Post-Graduate Training Director, Department of Psychiatry, University of Toronto; Psychiatrist, Sunnybrook Health Sciences Centre, Toronto, Ontario
| | - Anthony J Levitt
- Psychiatrist, Department of Psychiatry, Sunnybrook Health Sciences Centre; Professor, Department of Psychiatry, University of Toronto, Toronto, Ontario
| | - Ayal Schaffer
- Head, Mood and Anxiety Disorders Program, Department of Psychiatry, Sunnybrook Health Sciences Centre; Professor, Department of Psychiatry, University of Toronto, Toronto, Ontario
| |
Collapse
|
47
|
Sinyor M, Cheung CP, Abraha HY, Lanctôt KL, Saleem M, Liu CS, Li A, Juda A, Levitt AJ, Cheung AH, Schaffer A. Antidepressant-placebo differences for specific adverse events in major depressive disorder: A systematic review. J Affect Disord 2020; 267:185-190. [PMID: 32217218 DOI: 10.1016/j.jad.2020.02.013] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/12/2019] [Revised: 01/29/2020] [Accepted: 02/01/2020] [Indexed: 11/16/2022]
Abstract
BACKGROUND Adverse events (AEs) are known to occur while patients are treated with placebos, part of the so-called nocebo effect. Yet evidence is limited regarding the likelihood that specific AEs occurring with antidepressant treatment are or are not due to nocebo effects. METHODS This study identified 56 placebo-controlled, randomized controlled trials (RCTs) of antidepressant monotherapy for adults with major depressive disorder that reported AE rates in sufficient detail for comparison. Poisson regression analyses compared rates of AEs according to antidepressant class weighted by study population to determine which separated from placebo. A "nocebo index" was also calculated (with 0 defined as the lowest rate and 1 or higher indicating the same or greater rate of an AE in the placebo group). RESULTS Numerous AEs did not differ statistically between antidepressant classes and placebo including worsening psychiatric symptoms, all forms of pain, weight gain and respiratory symptoms. Nevertheless, a number of AEs were significantly more common in antidepressants than placebos across multiple antidepressant classes. These were predominantly neurological, sexual and anticholinergic effects. Several AEs that separated statistically between antidepressants and placebos nevertheless had moderate nocebo indices (≥0.5). For example, dizziness in SSRIs separated significantly from placebo (OR 1.50, 95%CI 1.13-1.99) but had a nocebo index of 0.67. LIMITATIONS This study relied on multiple RCTs with subtle design differences. CONCLUSIONS This study identified several AEs that are likely the physiological result of antidepressants and many that likely represent nocebo effects. These results should inform clinical decision making and discussions with patients.
Collapse
Affiliation(s)
- Mark Sinyor
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada.
| | - Christian P Cheung
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Haben Y Abraha
- Neuropsychopharmacology Research Program, Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Krista L Lanctôt
- Neuropsychopharmacology Research Program, Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Mahwesh Saleem
- Neuropsychopharmacology Research Program, Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Celina S Liu
- Neuropsychopharmacology Research Program, Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Abby Li
- Neuropsychopharmacology Research Program, Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Ari Juda
- Department of Psychiatry, University of Toronto, Toronto, Canada
| | - Anthony J Levitt
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada
| | - Amy H Cheung
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada
| | - Ayal Schaffer
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada
| |
Collapse
|
48
|
Affiliation(s)
- Ayal Schaffer
- Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada
| | - Anna Van Meter
- Department of Psychiatry Research, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, The Feinstein Institutes for Medical Research, The Zucker Hillside Hospital, Glen Oaks, New York
| | - Mark Sinyor
- Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada
| |
Collapse
|
49
|
Fotso Soh J, Almadani A, Beaulieu S, Rajji T, Mulsant BH, Su CL, Renaud S, Mucsi I, Torres-Platas SG, Levinson A, Schaffer A, Dols A, Cervantes P, Low N, Herrmann N, Mantere O, Rej S. The effect of atorvastatin on cognition and mood in bipolar disorder and unipolar depression patients: A secondary analysis of a randomized controlled trial. J Affect Disord 2020; 262:149-154. [PMID: 31733459 DOI: 10.1016/j.jad.2019.11.013] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/02/2019] [Revised: 10/03/2019] [Accepted: 11/02/2019] [Indexed: 12/22/2022]
Abstract
OBJECTIVES Statins have recently been linked to having effects on cognition and mood in mood disorders, though results are mixed. In this paper, we use data from a recent randomized controlled trial (RCT) to examine the effect of statins on cognition and mood in patients with Bipolar Disorder (BD) and Major Depressive Disorder (MDD). METHODS This is a secondary analysis of a randomized, double-blind, placebo-controlled clinical trial (n = 60) originally designed to examine the effect of atorvastatin (n = 27) versus placebo (n = 33) for lithium-induced diabetes insipidus in BD and MDD patients who were using lithium. For this analysis, the primary outcome was global cognition Z-score at 12-weeks adjusted for baseline. The secondary cognition outcomes were (1) Screen for Cognitive Impairment in Psychiatry (SCIP), and (2) executive function Z-score. The primary mood outcome (secondary outcome of this analysis) was depression relapse during 12-week follow-up (Mongomery Asberg Depression Rating Scale (MADRS) ≥10). The secondary mood outcomes were (1) relapse rate into a manic episode, and (2) relapse rate into any mood episode. RESULTS After 12 weeks follow-up, atorvastatin and placebo groups did not differ in terms of global cognition Z-score (β = -0.009287 (-0.1698,0.1512), p-value = 0.91). Similarly, composite Z-scores for SCIP and executive functions did not differ significantly. Depression relapse during 12-week follow-up was not significantly different between the groups (χ2 (1) = 0.148, p-value = 0.70). Similarly, there was no difference between groups regarding relapse into mania. CONCLUSION In BD and MDD patients with lithium-induced nephrogenic diabetes insipidus randomized to atorvastatin or placebo, we found no significant differences in cognition and mood outcomes at 12-week follow-up.
Collapse
Affiliation(s)
- Jocelyn Fotso Soh
- Geri-PARTy Research Group, Jewish General Hospital/Lady Davis Institute, McGill University, Montreal, Canada.
| | - Ahmad Almadani
- Department of Psychiatry, College of Medicine, King Saud University, Riyadh, Saudi Arabia; Department of Psychiatry, McGill University, Montreal, Canada
| | - Serge Beaulieu
- Douglas Mental Health University Institute, Montreal, QC, Canada
| | - Tarek Rajji
- Department of Psychiatry, Centre for Addictions and Mental Health, University of Toronto, Canada
| | | | - Chien-Lin Su
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University Health Centre, Montreal, Canada
| | - Suzane Renaud
- Douglas Mental Health University Institute, Montreal, QC, Canada
| | - Istvan Mucsi
- Division of Nephrology, University Health Network, University of Toronto, Canada
| | - S Gabriela Torres-Platas
- Geri-PARTy Research Group, Jewish General Hospital/Lady Davis Institute, McGill University, Montreal, Canada
| | - Andrea Levinson
- Department of Psychiatry, Centre for Addictions and Mental Health, University of Toronto, Canada
| | - Ayal Schaffer
- Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto, Canada
| | - Annemiek Dols
- Department of Psychiatry, GGZ, inGeest, Amsterdam, the Netherlands
| | - Pablo Cervantes
- Department of Psychiatry, McGill University Health Centre, Montreal, Canada
| | - Nancy Low
- Department of Psychiatry, McGill University Health Centre, Montreal, Canada
| | - Nathan Herrmann
- Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto, Canada
| | - Outi Mantere
- Department of Psychiatry, McGill University, Montreal, Canada; Douglas Mental Health University Institute, Montreal, QC, Canada
| | - Soham Rej
- Geri-PARTy Research Group, Jewish General Hospital/Lady Davis Institute, McGill University, Montreal, Canada; Douglas Mental Health University Institute, Montreal, QC, Canada
| |
Collapse
|
50
|
Miskowiak KW, Seeberg I, Kjaerstad HL, Burdick KE, Martinez-Aran A, Del Mar Bonnin C, Bowie CR, Carvalho AF, Gallagher P, Hasler G, Lafer B, López-Jaramillo C, Sumiyoshi T, McIntyre RS, Schaffer A, Porter RJ, Purdon S, Torres IJ, Yatham LN, Young AH, Kessing LV, Van Rheenen TE, Vieta E. Affective cognition in bipolar disorder: A systematic review by the ISBD targeting cognition task force. Bipolar Disord 2019; 21:686-719. [PMID: 31491048 DOI: 10.1111/bdi.12834] [Citation(s) in RCA: 56] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
BACKGROUND Impairments in affective cognition are part of the neurocognitive profile and possible treatment targets in bipolar disorder (BD), but the findings are heterogeneous. The International Society of Bipolar Disorder (ISBD) Targeting Cognition Task Force conducted a systematic review to (i) identify the most consistent findings in affective cognition in BD, and (ii) provide suggestions for affective cognitive domains for future study and meta-analyses. METHODS The review included original studies reporting behavioral measures of affective cognition in BD patients vs controls following the procedures of the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) statement. Searches were conducted on PubMed/MEDLINE, EMBASE, and PsychInfo from inception until November 2018. RESULTS A total of 106 articles were included (of which nine included data for several affective domains); 41 studies assessed emotional face processing; 23 studies investigated reactivity to emotional words and images; 3 investigated explicit emotion regulation; 17 assessed implicit emotion regulation; 31 assessed reward processing and affective decision making. In general, findings were inconsistent. The most consistent findings were trait-related difficulties in facial emotion recognition and implicit emotion regulation, and impairments in reward processing and affective decision making during mood episodes. Studies using eye-tracking and facial emotion analysis revealed subtle trait-related abnormalities in emotional reactivity. CONCLUSION The ISBD Task Force recommends facial expression recognition, implicit emotion regulation, and reward processing as domains for future research and meta-analyses. An important step to aid comparability between studies in the field would be to reach consensus on an affective cognition test battery for BD.
Collapse
Affiliation(s)
- Kamilla W Miskowiak
- Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.,Department of Psychology, University of Copenhagen, Copenhagen, Denmark
| | - Ida Seeberg
- Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.,Department of Psychology, University of Copenhagen, Copenhagen, Denmark
| | - Hanne L Kjaerstad
- Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
| | - Katherine E Burdick
- Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA.,Department of Psychiatry, Harvard Medical School, Boston, MA, USA
| | - Anabel Martinez-Aran
- Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain
| | - Caterina Del Mar Bonnin
- Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain
| | | | - Andre F Carvalho
- Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada.,Department of Psychiatry, University of Toronto, Toronto, Canada
| | - Peter Gallagher
- Institute of Neuroscience, Newcastle University, Newcastle-upon-Tyne, UK
| | - Gregor Hasler
- Psychiatry Research Unit, University of Fribourg, Fribourg, Switzerland
| | - Beny Lafer
- Bipolar Disorder Research Program, Departamento de Psiquiatria, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
| | - Carlos López-Jaramillo
- Research Group in Psychiatry, Department of Psychiatry, Universidad de Antioquia, Medellín, Colombia
| | - Tomiki Sumiyoshi
- Department of Clinical Epidemiology, Translational Medical Center, National Center of Neurology and Psychiatry, Tokyo, Japan
| | - Roger S McIntyre
- Mood Disorders Psychopharmacology Unit Brain and Cognition Discovery Foundation, University of Toronto, Toronto, Canada
| | - Ayal Schaffer
- Department of Psychiatry, University of Toronto, Toronto, Canada
| | - Richard J Porter
- Department of Psychological Medicine, University of Otago, Christchurch, New Zealand
| | - Scot Purdon
- Department of Psychiatry, University of Alberta, Edmonton, Canada
| | - Ivan J Torres
- Department of Psychiatry, University of British Columbia, Vancouver, Canada
| | - Lakshmi N Yatham
- Department of Psychiatry, University of British Columbia, Vancouver, Canada
| | - Allan H Young
- Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Lars V Kessing
- Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
| | - Tamsyn E Van Rheenen
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne, Carlton, Australia.,Centre for Mental Health, Faculty of Health, Arts and Design, Swinburne University, Australia
| | - Eduard Vieta
- Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain
| |
Collapse
|